ClinicalTrials.gg
CompletedNCT00141518DAPHNEUpdated Jul 18, 2016Results posted

Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact

A Phase 4 interventional study of Levodopa-carbidopa intestinal gel (LCIG) and CADD-Legacy® 1400 ambulatory infusion pump in Advanced Idiopathic Parkinson's Disease, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2016-07-18.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
77
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Parkinson Disease by AbbVie — 6 open to participants now, 9 under way, none of them phase 3. Parkinson Disease · AbbVie.

Enrollment
12th of 25
77 · median 63
Started
2006
the only one that year
Phase 4
Only one
of the 44
Registered
1st of 44
by date

Among the 44 studies in Parkinson Disease by AbbVie, this one is the 12th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2006, is the only one in phase 4, and was the 1st registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

6 of the 44 studies in Parkinson Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Parkinson Disease by AbbVie, or all of them as a file.
02

Study summary

The primary objective of this study is to collect health economic data depicting the initial levels and natural progression over time of resource usage, Parkinson's disease (PD)-related costs, and health related quality of life (HRQoL) for a cohort of advanced PD patients treated with Duodopa (levodopa-carbidopa in an intestinal gel formulation), of which about one-third were Duodopa-naïve prior to the start of the study.

03

Conditions studied

  • Advanced Idiopathic Parkinson's Disease

Browse trials for

Keywords

  • Health economics,Quality of life
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced idiopathic Parkinson's disease

Exclusion criteria

Exclusion Criteria:

  • Other diseases which might influence compliance or participation in the study
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    Duodopa Naïve

    Duodopa-naïve participants titrated to receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL \[100-200 mg levodopa\]); the continuous maintenance dose (usually 2-6 mL/hour \[40-120 mg levodopa/hour\]); and extra bolus doses, adjusted individually.

    Drug: Levodopa-carbidopa intestinal gel (LCIG) · Device: CADD-Legacy® 1400 ambulatory infusion pump · Device: percutaneous endoscopic gastrostomy tube (PEG tube) · Device: jejunal extension tube (J-tube)

  • Experimental
    Duodopa Non-naïve < 2 Years

    Duodopa non-naïve participants treated with Duodopa for \< 2 years receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL \[100-200 mg levodopa\]); the continuous maintenance dose (usually 2-6 mL/hour \[40-120 mg levodopa/hour\]); and extra bolus doses, adjusted individually.

    Drug: Levodopa-carbidopa intestinal gel (LCIG) · Device: CADD-Legacy® 1400 ambulatory infusion pump · Device: percutaneous endoscopic gastrostomy tube (PEG tube) · Device: jejunal extension tube (J-tube)

  • Experimental
    Duodopa Non-naïve ≥ 2 years

    Duodopa non-naïve participants treated with Duodopa for ≥ 2 years receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL \[100-200 mg levodopa\]); the continuous maintenance dose (usually 2-6 mL/hour \[40-120 mg levodopa/hour\]); and extra bolus doses, adjusted individually.

    Drug: Levodopa-carbidopa intestinal gel (LCIG) · Device: CADD-Legacy® 1400 ambulatory infusion pump · Device: percutaneous endoscopic gastrostomy tube (PEG tube) · Device: jejunal extension tube (J-tube)

Interventions

  • DrugLevodopa-carbidopa intestinal gel (LCIG)

    Also known as: DUOPA™ (carbidopa and levodopa Enteral Suspension), DUODOPA®, ABT-SLV187

  • DeviceCADD-Legacy® 1400 ambulatory infusion pump
  • Devicepercutaneous endoscopic gastrostomy tube (PEG tube)
  • Devicejejunal extension tube (J-tube)
06

What researchers measure

Primary outcomes

  1. Unified Parkinson's Disease Rating Scale (UPDRS) Total Score, and UPDRS Subscores I, II, III, and IV at Baseline and Month 12

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect); for Part IV, questions are measured on a 5- or 2-point scale (0 or 1). Part I score is the sum of answers to 'Mentation, Behavior and Mood' questions, with a score range from 0-16. Part II score is the sum of answers to 'Activities of Daily Living' questions, with a score range from 0-52. Part III score is the sum of answers to 'Motor Examination' questions, with a score range from 0-108. Part IV score is the sum of answers to 'Complications of Therapy' questions, with a score range from 0-23. Total Score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale, with a score range from 0-176. Higher scores are associated with more disability.

    Time frame: Baseline (Month -3), Month 12

  2. Euro QoL 5 Dimensions Quality of Life Instrument (EQ-5D) Descriptive Systems Summary Index Score at Baseline and Month 12

    The EQ-5D is a participant-answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 (worst health state) to 1.00 (perfect health state).

    Time frame: Baseline (Month -3), Month 12

  3. EQ-5D Visual Analog Scale (VAS) Score at Baseline and Month 12

    The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.' The scale was normalized to a scale of 0 to 1, with higher values indicating a better health state.

    Time frame: Baseline (Month -3), Month 12

  4. Total Monthly Cost Per Participant, in Swedish Crowns (SEK) 2010

    Total monthly costs include * Direct medical costs (inpatient care, outpatient care, and drug costs \[including Duodopa cost and cost of concomitant anti-PD medication\]). * Direct non-medical costs (nursing home, home help, personal assistance, informal care \[from family member or friend\] and transportation to inpatient, outpatient visits and nursing home). * Indirect costs (sick-leave and early retirement due to PD \[applied to individuals only up to the age of 65 since the main indirect cost item, early retirement due to disability, is only available for individuals 30-64 years old. Sixty-five is also a common retirement age in Sweden\]). The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.

    Time frame: Baseline (month -3) for Duodopa-naïve participants, then at Month 0, and monthly thereafter until study completion (up to 48 months) for all participants

  5. Monthly Drug Costs Per Participant, SEK 2010

    Drug costs include Duodopa cost and cost of concomitant anti-PD medication. Drug costs are a direct medical cost. The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.

    Time frame: Baseline (month -3) for Duodopa-naïve participants, then at Month 0, and monthly thereafter until study completion (up to 48 months) for all participants

  6. Monthly Direct Medical Cost (Excluding Drug Costs) Per Participant, SEK 2010

    Direct medical costs consist of inpatient care, outpatient care (visits to physician, nurse, physiotherapist, occupational therapist, dietitian, speech therapist, counselor, and phone consultations). The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.

    Time frame: Baseline (month -3) for Duodopa-naïve participants, then at Month 0, and monthly thereafter until study completion (up to 48 months) for all participants

  7. Direct Monthly Non-medical Costs Per Participant, SEK 2010

    Direct non-medical costs include nursing home, home help, personal assistance, informal care (from family member or friend) and transportation to inpatient, outpatient visits and nursing home. The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.

    Time frame: Baseline (month -3) for Duodopa-naïve participants, then at Month 0, and monthly thereafter until study completion (up to 48 months) for all participants

  8. Indirect Monthly Costs Per Participant (Only Applied to Participants Younger Than 65) by Study Month, SEK 2010

    Indirect costs consist of sick-leave and early retirement due to PD, are applied to individuals only up to the age of 65 since the main indirect cost item - early retirement due to disability - is only available for individuals 30-64 years old. Sixty-five is also a common retirement age in Sweden. The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.

    Time frame: Baseline (month -3) for Duodopa-naïve participants, then at Month 0, and monthly thereafter until Month 36

Secondary outcomes

  1. Modified Hoehn and Yahr Staging: Current Stage From Baseline to Month 36

    The current stage of PD was characterized according to Modified Hoehn and Yahr criteria, measured on the following 8-point scale for staging: 0=no signs of disease; 1=unilateral disease; 1.5=unilateral plus axial involvement; 2=bilateral disease; 2.5=mild bilateral disease; 3=mild to moderate bilateral disease; 4=severe disability; and 5=wheelchair bound or bedridden unless aided.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  2. Modified Hoehn and Yahr Staging: Best Stage From Baseline to Month 36

    The best PD stage that the participant experienced during the last month was characterized according to Modified Hoehn and Yahr criteria, measured on the following 8-point scale for staging: 0=no signs of disease; 1=unilateral disease; 1.5=unilateral plus axial involvement; 2=bilateral disease; 2.5=mild bilateral disease; 3=mild to moderate bilateral disease; 4=severe disability; and 5=wheelchair bound or bedridden unless aided.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  3. Modified Hoehn and Yahr Staging: Worst Stage From Baseline to Month 36

    The worst PD stage that the participant experienced during the last month was characterized according to Modified Hoehn and Yahr criteria, measured on the following 8-point scale for staging: 0=no signs of disease; 1=unilateral disease; 1.5=unilateral plus axial involvement; 2=bilateral disease; 2.5=mild bilateral disease; 3=mild to moderate bilateral disease; 4=severe disability; and 5=wheelchair bound or bedridden unless aided.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  4. Schwab and England Scale: Best "On" Period Stage From Baseline to Month 36

    The Schwab and England scale was used to rate the subject's best "on" period during the past week by recording the percentage score, ranging between being completely independent (100%) and totally dependent (10%). "On" time is when PD symptoms are well controlled by the drug.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  5. Mini Mental Status Examination (MMSE) Total Scores From Baseline to Month 36

    The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The test consists of five sections (orientation, registration, attention-calculation, recall, and language) and results in a total possible score of 0 to 30, with higher scores indicating better function.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint visit (Month 36 or last visit if discontinued early)

  6. MMSE Orientation Subscale Scores From Baseline to Month 36

    The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The orientation subscale has a total possible score of 0 to 10, with higher scores indicating better function.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  7. MMSE Registration Subscale Scores From Baseline to Month 36

    The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The Registration subscale a total possible score of 0 to 3, with higher scores indicating better function.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  8. MMSE Attention and Calculation Subscale Scores From Baseline to Month 36

    The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The Attention and Calculation subscale results in a total possible score of 0 to 5, with higher scores indicating better function.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  9. MMSE Recall Subscale Scores From Baseline to Month 36

    The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The Recall subscale results in a total possible score of 0 to 3, with higher scores indicating better function.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  10. MMSE Language Subscale Scores From Baseline to Month 36

    The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The Language subscale results in a total possible score of 0 to 9, with higher scores indicating better function.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  11. Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores From Baseline to Month 36

    MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Total score ranges from 0 (no depression) to 60 (severely depressed).

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  12. MADRS Reported Sadness Scores From Baseline to Month 36

    MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Reported Sadness scores rate depressed mood, regardless of whether it is reflected in appearance or not, and includes low spirits, despondency or the feeling of being beyond help and without hope.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  13. MADRS Apparent Sadness Scores From Baseline to Month 36

    MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Apparent sadness scores rate despondency, gloom and despair (more than just ordinary transient low spirits), reflected in speech, facial expression, and posture.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  14. MADRS Inner Tension Scores From Baseline to Month 36

    MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Inner Tension scores rate feelings of ill-defined discomfort, edginess, inner turmoil, mental tension mounting to either panic, dread or anguish.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  15. MADRS Reduced Sleep Scores From Baseline to Month 36

    MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Reduced Sleep scores rate the experience of reduced duration or depth of sleep compared to the participant's own normal pattern when well.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  16. MADRS Reduced Appetite Scores From Baseline to Month 36

    MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Reduced Appetite scores rate the feeling of a loss of appetite compared with when-well. Rate by loss of desire for food or the need to force oneself to eat.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  17. MADRS Concentration Difficulties Scores From Baseline to Month 36

    MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Concentration Difficulties scores rate difficulties in collecting one's thoughts mounting to an incapacitating lack of concentration.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  18. MADRS Lassitude Scores From Baseline to Month 36

    MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Lassitude scores rate difficulty in getting started or slowness in initiating and performing everyday activities.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  19. MADRS Inability to Feel Scores From Baseline to Month 36

    MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Inability to Feel scores rate the subjective experience of reduced interest in the surroundings, or activities that normally give pleasure. The ability to react with adequate emotion to circumstances or people is reduced.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  20. MADRS Pessimistic Thoughts Scores From Baseline to Month 36

    MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Pessimistic Thoughts scores rate thoughts of guilt, inferiority, self-reproach, sinfulness, remorse and ruin.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  21. MADRS Suicidal Thoughts Scores From Baseline to Month 36

    MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Suicidal Thoughts scores rate the feeling that life is not worth living, that a natural death would be welcome, suicidal thoughts, and preparations for suicide.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  22. Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index Scores From Baseline to Month 36

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible, which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  23. PDQ-39 Mobility Subscale Scores From Baseline to Month 36

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  24. PDQ-39 Activities of Daily Living Subscale Scores From Baseline to Month 36

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  25. PDQ-39 Emotional Well Being Subscale Scores From Baseline to Month 36

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  26. PDQ-39 Stigma Subscale Scores From Baseline to Month 36

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  27. PDQ-39 Social Support Subscale Scores From Baseline to Month 36

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  28. PDQ-39 Cognition Subscale Scores From Baseline to Month 36

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  29. PDQ-39 Communication Subscale Scores From Baseline to Month 36

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  30. PDQ-39 Bodily Discomfort Subscale Scores From Baseline to Month 36

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  31. Electronic Diary: Morning and Day Scores (Walking) From Baseline to Month 36

    The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Walking scores ranged from 1 (worst) to 5 (best).

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  32. Electronic Diary: Morning and Day Scores (Off Time) From Baseline to Month 36

    The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. "Off" time is when PD symptoms are not adequately controlled by the drug, and is represented as a percentage of total time awake per day.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  33. Electronic Diary: Morning and Day Scores (On Time) From Baseline to Month 36

    The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. "On" time is when PD symptoms are well controlled by the drug, and is represented as a percentage of total time of the last __ hours.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  34. Electronic Diary: Morning and Day Scores (Dyskinetic Time) From Baseline to Month 36

    The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Dyskinetic time' is time with involuntary muscle movement, and is represented as a percentage of total time of the last __ hours.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  35. Electronic Diary: Morning and Day Scores (Off Magnitude) From Baseline to Month 36

    The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Off time' is when PD symptoms are not adequately controlled by the drug. Magnitude scores were 1 (worst) to 5 (best).

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  36. Electronic Diary: Morning and Day Scores (Dyskinetic Magnitude) From Baseline to Month 36

    The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Dyskinetic time' is time with involuntary muscle movement. Magnitude scores were 1 (worst) to 5 (best).

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  37. Electronic Diary: Morning and Day Scores (Cramps) From Baseline to Month 36

    The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Cramps' scores were 1 (worst) to 5 (best).

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  38. Electronic Diary: Morning and Day Scores (Satisfied With Function) From Baseline to Month 36

    The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Satisfied with function' scores were 1 (worst) to 5 (best).

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  39. Electronic Diary: Morning and Day Scores (Self-assessment) From Baseline to Month 36

    The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Self-assessment' scores were -3 (Off) to +3 (dyskinetic). 'Off' time is when PD symptoms are not adequately controlled by the drug. 'Dyskinetic' time is time with involuntary muscle movement. "0" is defined as the normal ON state without dyskinesia (the desired motor state). Everything closer to "0" means improvement, everything more away from "0" means either less mobility (in the negative score) or involuntary movements (dyskinesia, in the positive score).

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  40. Electronic Diary: Morning and Day Scores (Free Tapping - Speed) From Baseline to Month 36

    The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Free tapping is defined as voluntary repetitive finger tapping on computer-generated fields. 'Free tapping speed' is a count of the number of taps per 20 seconds.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  41. Electronic Diary: Morning and Day Scores (Free Tapping - Accuracy) From Baseline to Month 36

    The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Free tapping' is defined as ____. 'Free tapping accuracy' is the percentage of accurate free taps per 20 seconds(?).

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  42. Electronic Diary: Morning and Day Scores (Tapping, Increased Speed - Accuracy) From Baseline to Month 36

    The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Tapping at increased speed - accuracy' is the percentage of accurate taps per all taps on computer-generated fields.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  43. Electronic Diary: Morning and Day Scores (Tapping, Random Chase - Speed) From Baseline to Month 36

    The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Tapping: Random chase speed' is defined as the number of correct taps of fields randomly selected by the computer per 20 seconds.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  44. Electronic Diary: Morning and Day Scores (Tapping, Random Chase - Accuracy) From Baseline to Month 36

    The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Tapping: Random chase speed' is defined as the number of correct taps of fields randomly selected by the computer per 20 seconds. 'Tapping random chase - accuracy' is the percentage of accurate random chase taps.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  45. Electronic Diary: Morning and Day Scores (Drawing Impairment [Wavelet Method]) From Baseline to Month 36

    The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Drawing impairment was assessed as a spiral score, where the participant is asked to draw a spiral. 1 is worst score, 10 is best.

    Time frame: Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

Other outcomes

  1. UPDRS Total Score up to Month 36

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Part I score is the sum of answers to 'Mentation, Behavior and Mood' questions, with a score range from 0-16. Part II score is the sum of answers to 'Activities of Daily Living' questions, with a score range from 0-52. Part III score is the sum of answers to 'Motor Examination' questions, with a score range from 0-108. Total Score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale, with a score range from 0-176. Higher scores are associated with more disability.

    Time frame: Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  2. UPDRS Part I Score, up to Month 36

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Part I score is the sum of answers to 'Mentation, Behavior and Mood' questions, with a score range from 0-16. Higher scores are associated with more disability.

    Time frame: Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  3. UPDRS Part II Score, up to Month 36

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Part II score is the sum of answers to 'Activities of Daily Living' questions, with a score range from 0-52. Higher scores are associated with more disability.

    Time frame: Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  4. UPDRS Part III Score, up to Month 36

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Part III score is the sum of answers to 'Motor Examination' questions, with a score range from 0-108. Higher scores are associated with more disability.

    Time frame: Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  5. UPDRS Part IV Score, up to Month 36

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Part IV, questions are measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect) or 2-point scale (0 or 1). Part IV score is the sum of answers to 'Complications of Therapy' questions, with a score range from 0-23. Higher scores are associated with more disability.

    Time frame: Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  6. EQ-5D Descriptive Systems Summary Index Score, up to Month 36

    The EQ-5D is a participant-answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 to 1.00 with positive change indicating improvement.

    Time frame: Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

  7. EQ-5D Visual Analog Scale (VAS) Score, up to Month 36

    The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.'

    Time frame: Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)

07

Results

Posted Jul 18, 2016

Participant flow

Participant flow — Overall Study
MilestoneDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Started372218
Safety sample362218
Full analysis sample272218
Completed211612
Not completed1666
Withdrew: Withdrew consent prior to treatment100
Withdrew: Adverse event752
Withdrew: Withdrawal by subject202
Withdrew: Protocol violation112
Withdrew: Lack of efficacy500

Outcome measures

PrimaryUnified Parkinson's Disease Rating Scale (UPDRS) Total Score, and UPDRS Subscores I, II, III, and IV at Baseline and Month 12

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect); for Part IV, questions are measured on a 5- or 2-point scale (0 or 1). Part I score is the sum of answers to 'Mentation, Behavior and Mood' questions, with a score range from 0-16. Part II score is the sum of answers to 'Activities of Daily Living' questions, with a score range from 0-52. Part III score is the sum of answers to 'Motor Examination' questions, with a score range from 0-108. Part IV score is the sum of answers to 'Complications of Therapy' questions, with a score range from 0-23. Total Score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale, with a score range from 0-176. Higher scores are associated with more disability.

Time frame:
Baseline (Month -3), Month 12
Reported as:
Mean · units on a scale
Unified Parkinson's Disease Rating Scale (UPDRS) Total Score, and UPDRS Subscores I, II, III, and IV at Baseline and Month 12
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Total Score, Baseline (Month -3); n=27, 0, 052.1 ± 16.1NA ± NANA ± NA
Total Score, Month 12; n=25, 20, 1742.5 ± 22.644.0 ± 13.948.2 ± 18.4
Part I, Baseline (Month -3); n=27, 0, 02.9 ± 1.9NA ± NANA ± NA
Part I, Month 12; n=25, 20, 173.1 ± 2.22.6 ± 2.03.2 ± 2.2
Part II, Baseline (Month -3); n=27, 0, 015.4 ± 5.7NA ± NANA ± NA
Part II, Month 12; n=25, 20, 1712.2 ± 6.813.4 ± 5.714.3 ± 6.0
Part III, Baseline (Month -3); n=27, 0, 024.4 ± 11.0NA ± NANA ± NA
Part III, Month 12; n=25, 20, 1721.5 ± 13.221.2 ± 10.023.5 ± 11.5
Part IV, Baseline (Month -3); n=27, 0, 09.4 ± 2.6NA ± NANA ± NA
Part IV, Month 12; n=25, 20, 175.7 ± 3.47.0 ± 2.57.2 ± 3.5
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 0.017 · Mean change from baseline: -9.4
PrimaryEuro QoL 5 Dimensions Quality of Life Instrument (EQ-5D) Descriptive Systems Summary Index Score at Baseline and Month 12

The EQ-5D is a participant-answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 (worst health state) to 1.00 (perfect health state).

Time frame:
Baseline (Month -3), Month 12
Reported as:
Mean · units on a scale
Euro QoL 5 Dimensions Quality of Life Instrument (EQ-5D) Descriptive Systems Summary Index Score at Baseline and Month 12
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=27, 0, 00.57 ± 0.26NA ± NANA ± NA
Month 12; n=25, 20, 170.59 ± 0.330.66 ± 0.360.51 ± 0.37
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 0.919 · Mean change from baseline: 0.02
PrimaryEQ-5D Visual Analog Scale (VAS) Score at Baseline and Month 12

The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.' The scale was normalized to a scale of 0 to 1, with higher values indicating a better health state.

Time frame:
Baseline (Month -3), Month 12
Reported as:
Mean · units on a scale
EQ-5D Visual Analog Scale (VAS) Score at Baseline and Month 12
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=27, 0, 00.44 ± 0.20NA ± NANA ± NA
Month 12; n=25, 19, 170.63 ± 0.180.64 ± 0.190.64 ± 0.22
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 0.002 · Mean change from baseline: 0.18
PrimaryTotal Monthly Cost Per Participant, in Swedish Crowns (SEK) 2010

Total monthly costs include * Direct medical costs (inpatient care, outpatient care, and drug costs \[including Duodopa cost and cost of concomitant anti-PD medication\]). * Direct non-medical costs (nursing home, home help, personal assistance, informal care \[from family member or friend\] and transportation to inpatient, outpatient visits and nursing home). * Indirect costs (sick-leave and early retirement due to PD \[applied to individuals only up to the age of 65 since the main indirect cost item, early retirement due to disability, is only available for individuals 30-64 years old. Sixty-five is also a common retirement age in Sweden\]). The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.

Time frame:
Baseline (month -3) for Duodopa-naïve participants, then at Month 0, and monthly thereafter until study completion (up to 48 months) for all participants
Reported as:
Mean · SEK 2010
Total Monthly Cost Per Participant, in Swedish Crowns (SEK) 2010
SEK 2010Duodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 YearsTotal
Total Monthly Cost Per Participant, in Swedish Crowns (SEK) 201078418 ± 4202875521 ± 7329682177 ± 5372878464 ± 56772
PrimaryMonthly Drug Costs Per Participant, SEK 2010

Drug costs include Duodopa cost and cost of concomitant anti-PD medication. Drug costs are a direct medical cost. The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.

Time frame:
Baseline (month -3) for Duodopa-naïve participants, then at Month 0, and monthly thereafter until study completion (up to 48 months) for all participants
Reported as:
Mean · SEK 2010
Monthly Drug Costs Per Participant, SEK 2010
SEK 2010Duodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 YearsTotal
Monthly Drug Costs Per Participant, SEK 201039382 ± 1673334417 ± 1049437679 ± 1519637339 ± 14725
PrimaryMonthly Direct Medical Cost (Excluding Drug Costs) Per Participant, SEK 2010

Direct medical costs consist of inpatient care, outpatient care (visits to physician, nurse, physiotherapist, occupational therapist, dietitian, speech therapist, counselor, and phone consultations). The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.

Time frame:
Baseline (month -3) for Duodopa-naïve participants, then at Month 0, and monthly thereafter until study completion (up to 48 months) for all participants
Reported as:
Mean · SEK 2010
Monthly Direct Medical Cost (Excluding Drug Costs) Per Participant, SEK 2010
SEK 2010Duodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 YearsTotal
Monthly Direct Medical Cost (Excluding Drug Costs) Per Participant, SEK 20103825 ± 93944552 ± 118193607 ± 86484002 ± 10069
PrimaryDirect Monthly Non-medical Costs Per Participant, SEK 2010

Direct non-medical costs include nursing home, home help, personal assistance, informal care (from family member or friend) and transportation to inpatient, outpatient visits and nursing home. The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.

Time frame:
Baseline (month -3) for Duodopa-naïve participants, then at Month 0, and monthly thereafter until study completion (up to 48 months) for all participants
Reported as:
Mean · SEK 2010
Direct Monthly Non-medical Costs Per Participant, SEK 2010
SEK 2010Duodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 YearsTotal
Direct Monthly Non-medical Costs Per Participant, SEK 201019274 ± 2648527439 ± 6165625008 ± 4245523398 ± 44698
PrimaryIndirect Monthly Costs Per Participant (Only Applied to Participants Younger Than 65) by Study Month, SEK 2010

Indirect costs consist of sick-leave and early retirement due to PD, are applied to individuals only up to the age of 65 since the main indirect cost item - early retirement due to disability - is only available for individuals 30-64 years old. Sixty-five is also a common retirement age in Sweden. The average rate for US Dollar (USD) to SEK on 31 December 2010 was 1 USD = 6.734 SEK.

Time frame:
Baseline (month -3) for Duodopa-naïve participants, then at Month 0, and monthly thereafter until Month 36
Reported as:
Mean · SEK 2010
Indirect Monthly Costs Per Participant (Only Applied to Participants Younger Than 65) by Study Month, SEK 2010
SEK 2010Total
Month -3; n=15/3717032 ± 20911
Month 0; n=23/6714109 ± 19823
Month 1; n=23/6714109 ± 19823
Month 2; n=22/6513896 ± 19746
Month 3; n=23/6514543 ± 19971
Month 4; n=23/6514543 ± 19971
Month 5; n=22/6513896 ± 19746
Month 6; n=21/6513250 ± 19498
Month 7; n=24/6515512 ± 20433
Month 8; n=24/6316005 ± 20566
Month 9; n=22/6214569 ± 19978
Month 10; n=22/6214569 ± 19978
Month 11; n=22/6214399 ± 19785
Month 12; n=22/6214399 ± 19785
Month 13; n=22/6214230 ± 19681
Month 14; n=22/6214569 ± 19978
Month 15; n=22/6114808 ± 20055
Month 16; n=22/6114808 ± 20055
Month 17; n=22/6114463 ± 19758
Month 18; n=22/6114463 ± 19758
Month 19; n=22/6014704 ± 19834
Month 20; n=20/5913529 ± 19411
Month 21; n=20/5813763 ± 19497
Month 22; n=18/5712530 ± 18980
Month 23; n=18/5712530 ± 18980
Month 24; n=17/5612003 ± 18727
Month 25; n=16/5412059 ± 18966
Month 26; n=18/5413615 ± 19637
Month 27; n=16/5312683 ± 19471
Month 28; n=15/5311890 ± 19106
Month 29; n=16/5312683 ± 19471
Month 30; n=16/5312683 ± 19471
Month 31; n=15/5012604 ± 19448
Month 32; n=14/5011763 ± 19055
Month 33; n=14/5011763 ± 19055
Month 34; n=14/4912003 ± 19176
Month 35; n=14/4912003 ± 19176
Month 36; n=15/4912432 ± 19137
SecondaryModified Hoehn and Yahr Staging: Current Stage From Baseline to Month 36

The current stage of PD was characterized according to Modified Hoehn and Yahr criteria, measured on the following 8-point scale for staging: 0=no signs of disease; 1=unilateral disease; 1.5=unilateral plus axial involvement; 2=bilateral disease; 2.5=mild bilateral disease; 3=mild to moderate bilateral disease; 4=severe disability; and 5=wheelchair bound or bedridden unless aided.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
Modified Hoehn and Yahr Staging: Current Stage From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=27, 0, 02.7 ± 0.7NA ± NANA ± NA
Month 0; n=27, 22, 182.5 ± 0.72.7 ± 0.83.2 ± 0.8
Month 3; n=24, 22, 182.3 ± 0.82.7 ± 0.83.0 ± 0.8
Month 6; n=25, 22, 182.4 ± 0.82.6 ± 0.93.1 ± 0.8
Month 9; n=25, 20, 172.4 ± 1.02.7 ± 0.73.1 ± 0.7
Month 12; n=25, 20, 172.4 ± 0.82.8 ± 0.73.3 ± 0.8
Month 18; n=24, 20, 172.4 ± 0.92.7 ± 0.73.4 ± 1.0
Month 24; 23, 18, 152.5 ± 0.93.0 ± 0.93.2 ± 0.8
Month 30; n=23, 17, 132.7 ± 1.12.9 ± 0.83.1 ± 0.9
Month 36; n=21, 16, 122.7 ± 1.22.9 ± 0.63.3 ± 0.9
Endpoint; n=27, 22, 182.7 ± 1.13.1 ± 0.83.4 ± 0.8
SecondaryModified Hoehn and Yahr Staging: Best Stage From Baseline to Month 36

The best PD stage that the participant experienced during the last month was characterized according to Modified Hoehn and Yahr criteria, measured on the following 8-point scale for staging: 0=no signs of disease; 1=unilateral disease; 1.5=unilateral plus axial involvement; 2=bilateral disease; 2.5=mild bilateral disease; 3=mild to moderate bilateral disease; 4=severe disability; and 5=wheelchair bound or bedridden unless aided.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
Modified Hoehn and Yahr Staging: Best Stage From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=27, 0, 02.2 ± 1.2NA ± NANA ± NA
Month 0; n=27, 22, 182.0 ± 0.92.5 ± 0.72.5 ± 0.7
Month 3; n=24, 22, 182.0 ± 0.92.5 ± 0.62.6 ± 0.8
Month 6; n=25, 22, 182.0 ± 0.82.5 ± 0.72.6 ± 0.9
Month 9; 25, 20, 172.2 ± 1.12.5 ± 0.72.7 ± 0.7
Month 12; n=25, 20, 172.2 ± 0.82.6 ± 0.92.9 ± 0.8
Month 18; n=24, 20, 172.2 ± 0.92.5 ± 0.92.9 ± 0.9
Month 24; n=23, 18, 152.3 ± 1.12.6 ± 1.02.9 ± 0.8
Month 30; n=23, 17, 132.5 ± 1.22.6 ± 1.03.0 ± 0.9
Month 36; n=21, 16, 122.5 ± 1.32.6 ± 0.63.0 ± 0.7
Endpoint; n=27, 22, 182.6 ± 1.22.7 ± 0.73.1 ± 0.8
SecondaryModified Hoehn and Yahr Staging: Worst Stage From Baseline to Month 36

The worst PD stage that the participant experienced during the last month was characterized according to Modified Hoehn and Yahr criteria, measured on the following 8-point scale for staging: 0=no signs of disease; 1=unilateral disease; 1.5=unilateral plus axial involvement; 2=bilateral disease; 2.5=mild bilateral disease; 3=mild to moderate bilateral disease; 4=severe disability; and 5=wheelchair bound or bedridden unless aided.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
Modified Hoehn and Yahr Staging: Worst Stage From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=27, 0, 03.8 ± 1.0NA ± NANA ± NA
Month 0; n=27, 22, 183.6 ± 1.13.7 ± 0.94.0 ± 0.6
Month 3; n=24, 22, 183.8 ± 1.23.7 ± 0.94.1 ± 0.7
Month 6; n=25, 22, 183.7 ± 1.33.7 ± 1.14.0 ± 0.7
Month 9; n=25, 20, 173.7 ± 1.23.8 ± 0.74.0 ± 0.5
Month 12; n=25, 20, 173.6 ± 1.33.8 ± 0.84.2 ± 0.5
Month 18; n=24, 20, 173.8 ± 1.33.9 ± 0.84.3 ± 0.6
Month 24; n=23, 18, 153.9 ± 1.33.8 ± 0.84.4 ± 0.5
Month 30; n=23, 17, 134.0 ± 1.14.0 ± 0.84.5 ± 0.7
Month 36; n=21, 16, 123.9 ± 1.24.0 ± 0.64.6 ± 0.5
Endpoint; n=27, 22, 183.9 ± 1.14.0 ± 0.74.5 ± 0.5
SecondarySchwab and England Scale: Best "On" Period Stage From Baseline to Month 36

The Schwab and England scale was used to rate the subject's best "on" period during the past week by recording the percentage score, ranging between being completely independent (100%) and totally dependent (10%). "On" time is when PD symptoms are well controlled by the drug.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · percentage score on a scale
Schwab and England Scale: Best "On" Period Stage From Baseline to Month 36
percentage score on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=27, 0, 074.4 ± 15.8NA ± NANA ± NA
Month 0; n=27, 22, 1880.4 ± 13.275.5 ± 14.474.4 ± 11.5
Month 3; n=24, 22, 1877.9 ± 14.475.9 ± 14.472.2 ± 15.2
Month 6; n=25, 22, 1875.2 ± 15.377.3 ± 11.672.2 ± 12.6
Month 9; n=25, 20, 1779.2 ± 13.576.5 ± 13.170.6 ± 13.0
Month 12; n=25, 20, 1777.2 ± 13.472.5 ± 15.971.8 ± 12.4
Month 18; n=24, 20, 1775.8 ± 12.874.0 ± 11.969.4 ± 14.3
Month 24; n=23, 18, 1572.2 ± 18.173.3 ± 14.668.0 ± 15.2
Month 30; n=23, 17, 1370.4 ± 18.771.8 ± 16.767.7 ± 17.9
Month 36; n=21, 16, 1266.7 ± 21.173.1 ± 13.064.2 ± 21.1
Endpoint; n=27, 22, 1868.9 ± 19.571.4 ± 13.262.2 ± 17.7
SecondaryMini Mental Status Examination (MMSE) Total Scores From Baseline to Month 36

The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The test consists of five sections (orientation, registration, attention-calculation, recall, and language) and results in a total possible score of 0 to 30, with higher scores indicating better function.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint visit (Month 36 or last visit if discontinued early)
Reported as:
Mean · units on a scale
Mini Mental Status Examination (MMSE) Total Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=26, 0, 028.2 ± 2.2NA ± NANA ± NA
Month 0; n=27, 22, 1827.8 ± 2.428.0 ± 2.228.2 ± 1.4
Month 3; n=24, 22, 1828.0 ± 2.927.2 ± 2.828.6 ± 1.9
Month 6; n=25, 21, 1828.1 ± 2.527.6 ± 1.928.1 ± 1.4
Month 9; n=25, 20, 1728.4 ± 2.327.6 ± 2.028.3 ± 2.1
Month 12; n=25, 20, 1727.9 ± 2.828.2 ± 1.728.2 ± 2.5
Month 18; n=24, 19, 1627.6 ± 2.728.5 ± 1.428.3 ± 2.3
Month 24; n=23, 18, 1527.7 ± 2.527.8 ± 2.028.0 ± 2.2
Month 30; n=23, 17, 1327.3 ± 3.926.4 ± 3.428.6 ± 2.0
Month 36; n=21, 16, 1227.2 ± 3.226.3 ± 4.027.9 ± 4.1
Endpoint; n=27, 22, 1727.1 ± 3.926.4 ± 3.827.3 ± 3.8
SecondaryMMSE Orientation Subscale Scores From Baseline to Month 36

The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The orientation subscale has a total possible score of 0 to 10, with higher scores indicating better function.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
MMSE Orientation Subscale Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=26, 0, 09.8 ± 0.6NA ± NANA ± NA
Month 0; n=27, 22, 189.6 ± 1.19.9 ± 0.49.8 ± 0.4
Month 3; n=24, 22, 189.4 ± 1.29.5 ± 1.19.6 ± 0.6
Month 6; n=25, 21, 189.7 ± 0.79.6 ± 0.99.7 ± 0.6
Month 9; n=25, 20, 179.8 ± 0.59.9 ± 0.49.6 ± 1.0
Month 12; n=25, 20, 179.6 ± 1.19.8 ± 0.69.7 ± 1.0
Month 18; n=24, 19, 169.7 ± 0.79.7 ± 0.69.9 ± 0.3
Month 24; n=23, 18, 159.7 ± 0.69.8 ± 0.59.9 ± 0.4
Month 30; n=23, 17, 139.4 ± 1.28.9 ± 1.99.8 ± 0.6
Month 36; n=21, 16, 129.6 ± 1.09.3 ± 1.29.1 ± 2.2
Endpoint; n=27, 22, 179.5 ± 1.18.9 ± 1.69.2 ± 1.8
SecondaryMMSE Registration Subscale Scores From Baseline to Month 36

The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The Registration subscale a total possible score of 0 to 3, with higher scores indicating better function.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
MMSE Registration Subscale Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=26, 0, 03.0 ± 0.0NA ± NANA ± NA
Month 0; n=27, 22, 183.0 ± 0.23.0 ± 0.23.0 ± 0.0
Month 3; n=24, 22, 183.0 ± 0.03.0 ± 0.23.0 ± 0.0
Month 6; n=25, 21, 183.0 ± 0.03.0 ± 0.03.0 ± 0.0
Month 9; n=25, 20, 173.0 ± 0.03.0 ± 0.03.0 ± 0.0
Month 12; n=25, 20, 173.0 ± 0.23.0 ± 0.03.0 ± 0.0
Month 18; n=24, 19, 163.0 ± 0.03.0 ± 0.03.0 ± 0.0
Month 24; n=23, 18, 153.0 ± 0.23.0 ± 0.03.0 ± 0.0
Month 30; n=23, 17, 133.0 ± 0.02.9 ± 0.23.0 ± 0.0
Month 36; n=21, 16, 123.0 ± 0.03.0 ± 0.02.9 ± 0.3
Endpoint; n=27, 22, 173.0 ± 0.03.0 ± 0.02.9 ± 0.2
SecondaryMMSE Attention and Calculation Subscale Scores From Baseline to Month 36

The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The Attention and Calculation subscale results in a total possible score of 0 to 5, with higher scores indicating better function.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
MMSE Attention and Calculation Subscale Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=26, 0, 04.9 ± 0.4NA ± NANA ± NA
Month 0; n=27, 22, 184.6 ± 0.94.4 ± 1.44.6 ± 0.7
Month 3; n=24, 22, 184.6 ± 0.94.3 ± 1.34.7 ± 0.8
Month 6; n=25, 21, 184.6 ± 1.04.5 ± 0.84.7 ± 0.6
Month 9; n=25, 20, 174.7 ± 0.64.3 ± 1.04.8 ± 0.5
Month 12; n=25, 20, 174.7 ± 0.64.7 ± 0.74.6 ± 0.7
Month 18; n=24, 19, 164.5 ± 1.14.7 ± 0.84.5 ± 1.1
Month 24; n=23, 18, 154.6 ± 0.74.6 ± 0.64.3 ± 1.2
Month 30; n=23, 17, 134.6 ± 1.04.1 ± 1.24.8 ± 0.4
Month 36; n=21, 16, 124.2 ± 1.53.7 ± 1.94.8 ± 0.6
Endpoint; n=27, 22, 174.2 ± 1.54.0 ± 1.74.4 ± 0.9
SecondaryMMSE Recall Subscale Scores From Baseline to Month 36

The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The Recall subscale results in a total possible score of 0 to 3, with higher scores indicating better function.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
MMSE Recall Subscale Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=26, 0, 02.2 ± 0.9NA ± NANA ± NA
Month 0; n=27, 22, 182.2 ± 1.02.1 ± 0.82.3 ± 0.8
Month 3; n=24, 22, 182.5 ± 0.92.1 ± 0.92.5 ± 0.6
Month 6; n=25, 21, 182.5 ± 0.82.4 ± 0.82.3 ± 0.8
Month 9; n=25, 20, 172.5 ± 0.82.2 ± 0.82.5 ± 0.9
Month 12; n=25, 20, 172.5 ± 0.92.5 ± 0.82.6 ± 0.9
Month 18; n=24, 19, 162.3 ± 0.72.5 ± 0.52.6 ± 0.9
Month 24; n=23, 18, 152.4 ± 0.82.3 ± 0.82.5 ± 0.9
Month 30; n=23, 17, 132.5 ± 0.92.5 ± 0.62.6 ± 0.8
Month 36; n=21, 16, 122.2 ± 0.92.4 ± 0.72.8 ± 0.5
Endpoint; n=27, 22, 172.2 ± 0.92.5 ± 0.72.5 ± 0.8
SecondaryMMSE Language Subscale Scores From Baseline to Month 36

The MMSE is used to assess orientation, attention, immediate and short term recall, language, and ability to follow simple verbal and written commands. The Language subscale results in a total possible score of 0 to 9, with higher scores indicating better function.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
MMSE Language Subscale Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=26, 0, 08.3 ± 1.6NA ± NANA ± NA
Month 0; n=27, 22, 188.5 ± 0.98.6 ± 0.58.5 ± 0.7
Month 3; n=24, 22, 188.4 ± 0.78.3 ± 0.98.7 ± 0.5
Month 6; n=25, 21, 188.3 ± 0.98.1 ± 1.38.3 ± 0.7
Month 9; n=25, 20, 178.4 ± 1.08.2 ± 0.98.4 ± 0.7
Month 12; n=25, 20, 178.2 ± 1.38.3 ± 0.78.2 ± 0.8
Month 18; n=24, 19, 168.2 ± 1.18.6 ± 0.68.3 ± 0.9
Month 24; n=23, 18, 158.0 ± 1.48.1 ± 0.98.3 ± 0.8
Month 30; n=23, 17, 137.9 ± 1.48.0 ± 0.98.5 ± 1.0
Month 36; n=21, 16, 128.3 ± 0.97.9 ± 1.38.4 ± 1.0
Endpoint; n=27, 22, 178.3 ± 0.97.9 ± 1.38.4 ± 1.0
SecondaryMontgomery-Åsberg Depression Rating Scale (MADRS) Total Scores From Baseline to Month 36

MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Total score ranges from 0 (no depression) to 60 (severely depressed).

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=26, 0, 010.3 ± 5.6NA ± NANA ± NA
Month 0; n=27, 22, 189.0 ± 5.37.8 ± 5.28.8 ± 5.8
Month 3; n=24, 22, 1710.2 ± 6.38.1 ± 4.98.4 ± 5.8
Month 6; n=25, 21, 1710.5 ± 6.98.4 ± 3.88.5 ± 5.3
Month 9; n=25, 20, 178.8 ± 4.98.0 ± 3.49.9 ± 6.5
Month 12; n=25, 20, 178.6 ± 5.78.8 ± 5.29.5 ± 7.3
Month 18; n=24, 19, 1610.6 ± 6.28.1 ± 4.59.1 ± 7.1
Month 24; n=23, 18, 1510.1 ± 5.69.7 ± 5.511.1 ± 7.4
Month 30; n=22, 17, 1312.0 ± 5.910.6 ± 4.69.0 ± 5.0
Month 36; n=21, 16, 1212.2 ± 7.39.1 ± 4.510.4 ± 9.4
Endpoint; n=26, 22, 1711.6 ± 7.09.0 ± 4.912.3 ± 9.1
SecondaryMADRS Reported Sadness Scores From Baseline to Month 36

MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Reported Sadness scores rate depressed mood, regardless of whether it is reflected in appearance or not, and includes low spirits, despondency or the feeling of being beyond help and without hope.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
MADRS Reported Sadness Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=26, 0, 00.9 ± 0.8NA ± NANA ± NA
Month 0; n=27, 22, 180.6 ± 0.70.8 ± 1.20.8 ± 1.0
Month 3; n=24, 22, 170.9 ± 1.00.6 ± 0.80.5 ± 0.6
Month 6; n=25, 21, 171.1 ± 1.10.8 ± 0.60.5 ± 0.7
Month 9; n=25, 20, 170.9 ± 0.70.9 ± 0.81.1 ± 1.4
Month 12; n=25, 20, 170.6 ± 0.71.1 ± 0.90.8 ± 1.0
Month 18; n=24, 19, 161.0 ± 1.00.7 ± 0.70.8 ± 0.8
Month 24; n=23, 18, 151.0 ± 1.00.9 ± 0.90.8 ± 0.7
Month 30; n=23, 17, 131.2 ± 0.90.9 ± 0.80.9 ± 1.0
Month 36; n=21, 16, 121.1 ± 1.20.9 ± 0.91.1 ± 1.1
Endpoint; n=27, 22, 171.2 ± 1.20.8 ± 0.91.0 ± 1.0
SecondaryMADRS Apparent Sadness Scores From Baseline to Month 36

MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Apparent sadness scores rate despondency, gloom and despair (more than just ordinary transient low spirits), reflected in speech, facial expression, and posture.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
MADRS Apparent Sadness Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=26, 0, 00.7 ± 0.8NA ± NANA ± NA
Month 0; n=27, 22, 180.4 ± 0.80.5 ± 0.90.8 ± 0.7
Month 3; n=24, 22, 170.8 ± 0.90.6 ± 0.80.5 ± 0.7
Month 6; n=25, 21, 171.0 ± 1.10.6 ± 0.50.5 ± 0.6
Month 9; n=25, 20, 170.9 ± 0.80.7 ± 0.70.9 ± 1.0
Month 12; n=25, 20, 170.4 ± 0.50.9 ± 1.00.8 ± 0.8
Month 18; n=24, 19, 160.8 ± 0.90.6 ± 0.70.8 ± 0.9
Month 24; n=23, 18, 151.0 ± 1.20.6 ± 0.70.7 ± 0.6
Month 30; n=23, 17, 131.2 ± 1.01.0 ± 0.90.6 ± 0.7
Month 36; n=21, 16, 121.1 ± 1.20.8 ± 0.91.3 ± 1.4
Endpoint; n=27, 22, 171.1 ± 1.20.8 ± 1.01.0 ± 1.2
SecondaryMADRS Inner Tension Scores From Baseline to Month 36

MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Inner Tension scores rate feelings of ill-defined discomfort, edginess, inner turmoil, mental tension mounting to either panic, dread or anguish.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
MADRS Inner Tension Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=26, 0, 01.3 ± 1.3NA ± NANA ± NA
Month 0; n=27, 22, 181.3 ± 1.11.0 ± 1.00.9 ± 1.0
Month 3; n=24, 22, 171.5 ± 1.30.8 ± 1.00.9 ± 1.0
Month 6; n=25, 21, 171.1 ± 1.10.9 ± 1.01.2 ± 1.1
Month 9; n=25, 20, 170.9 ± 1.20.6 ± 0.80.9 ± 1.1
Month 12; n=25, 20, 171.1 ± 1.10.7 ± 0.91.5 ± 1.0
Month 18; n=24, 19, 161.2 ± 1.10.7 ± 0.90.8 ± 1.0
Month 24; n=23, 18, 151.0 ± 1.10.8 ± 1.11.3 ± 1.3
Month 30; n=23, 17, 131.1 ± 1.11.1 ± 1.21.5 ± 1.1
Month 36; n=21, 16, 121.7 ± 1.20.6 ± 0.81.3 ± 1.2
Endpoint; n=27, 22, 171.6 ± 1.10.6 ± 0.81.5 ± 1.3
SecondaryMADRS Reduced Sleep Scores From Baseline to Month 36

MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Reduced Sleep scores rate the experience of reduced duration or depth of sleep compared to the participant's own normal pattern when well.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
MADRS Reduced Sleep Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=26, 0, 02.5 ± 1.7NA ± NANA ± NA
Month 0; n=27, 22, 181.9 ± 1.61.5 ± 1.61.7 ± 1.8
Month 3; n=24, 22, 172.0 ± 1.41.8 ± 1.61.2 ± 1.2
Month 6; n=25, 21, 171.8 ± 1.81.7 ± 1.51.5 ± 1.7
Month 9; n=25, 20, 171.8 ± 1.51.9 ± 1.31.4 ± 1.5
Month 12; n=25, 20, 171.8 ± 1.51.5 ± 1.51.2 ± 1.4
Month 18; n=24, 19, 161.7 ± 1.31.5 ± 1.51.7 ± 1.4
Month 24; n=23, 18, 151.6 ± 1.31.8 ± 1.91.5 ± 1.7
Month 30; n=23, 17, 132.3 ± 1.71.9 ± 1.90.9 ± 1.0
Month 36; n=21, 16, 121.9 ± 1.71.2 ± 1.41.2 ± 1.5
Endpoint; n=27, 22, 171.6 ± 1.71.4 ± 1.52.0 ± 2.2
SecondaryMADRS Reduced Appetite Scores From Baseline to Month 36

MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Reduced Appetite scores rate the feeling of a loss of appetite compared with when-well. Rate by loss of desire for food or the need to force oneself to eat.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
MADRS Reduced Appetite Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=26, 0, 00.8 ± 1.1NA ± NANA ± NA
Month 0; n=27, 22, 180.6 ± 0.80.2 ± 0.50.3 ± 0.8
Month 3; n=24, 22, 170.7 ± 1.00.4 ± 0.80.4 ± 1.0
Month 6; n=25, 21, 170.8 ± 1.10.3 ± 0.70.5 ± 1.2
Month 9; n=25, 20, 170.5 ± 0.80.4 ± 0.60.8 ± 1.4
Month 12; n=25, 20, 170.5 ± 0.80.6 ± 0.80.7 ± 1.2
Month 18; n=24, 19, 160.5 ± 0.80.3 ± 0.70.4 ± 0.9
Month 24; n=23, 18, 150.7 ± 1.20.5 ± 0.80.7 ± 1.1
Month 30; n=23, 17, 131.0 ± 1.20.4 ± 0.60.5 ± 1.1
Month 36; n=21, 16, 120.9 ± 1.20.4 ± 0.71.1 ± 1.4
Endpoint; n=27, 22, 170.9 ± 1.20.3 ± 0.61.1 ± 1.3
SecondaryMADRS Concentration Difficulties Scores From Baseline to Month 36

MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Concentration Difficulties scores rate difficulties in collecting one's thoughts mounting to an incapacitating lack of concentration.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
MADRS Concentration Difficulties Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=26, 0, 01.0 ± 1.0NA ± NANA ± NA
Month 0; n=27, 22, 181.0 ± 1.21.5 ± 1.30.9 ± 1.2
Month 3; n=24, 22, 170.9 ± 1.11.3 ± 0.91.2 ± 1.2
Month 6; n=25, 21, 171.2 ± 1.21.4 ± 0.91.2 ± 1.1
Month 9; n=25, 20, 171.0 ± 1.21.1 ± 1.11.3 ± 1.2
Month 12; n=25, 20, 170.9 ± 1.21.2 ± 1.11.4 ± 1.3
Month 18; n=24, 19, 161.5 ± 1.41.4 ± 1.01.4 ± 1.3
Month 24; n=23, 18, 151.5 ± 1.31.7 ± 1.51.7 ± 1.4
Month 30; n=23, 17, 131.5 ± 1.72.1 ± 1.11.5 ± 1.5
Month 36; n=21, 16, 121.6 ± 1.31.9 ± 1.31.2 ± 1.7
Endpoint; n=27, 22, 171.6 ± 1.51.7 ± 1.31.6 ± 1.7
SecondaryMADRS Lassitude Scores From Baseline to Month 36

MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Lassitude scores rate difficulty in getting started or slowness in initiating and performing everyday activities.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
MADRS Lassitude Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=26, 0, 01.3 ± 1.4NA ± NANA ± NA
Month 0; n=27, 22, 181.4 ± 1.31.4 ± 1.21.7 ± 1.5
Month 3; n=24, 22, 171.7 ± 1.31.5 ± 1.02.0 ± 1.6
Month 6; n=25, 21, 171.5 ± 1.31.5 ± 1.21.3 ± 1.5
Month 9; n=25, 20, 171.3 ± 1.21.5 ± 1.21.7 ± 1.2
Month 12; n=25, 20, 171.6 ± 1.41.6 ± 1.31.4 ± 1.6
Month 18; n=24, 19, 161.8 ± 1.61.4 ± 1.21.6 ± 1.1
Month 24; n=23, 18, 151.7 ± 1.51.9 ± 1.11.7 ± 1.4
Month 30; n=23, 17, 132.0 ± 1.41.7 ± 1.31.3 ± 1.1
Month 36; n=21, 16, 121.9 ± 1.51.8 ± 1.41.7 ± 1.4
Endpoint; n=27, 22, 171.8 ± 1.51.7 ± 1.41.7 ± 1.4
SecondaryMADRS Inability to Feel Scores From Baseline to Month 36

MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Inability to Feel scores rate the subjective experience of reduced interest in the surroundings, or activities that normally give pleasure. The ability to react with adequate emotion to circumstances or people is reduced.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
MADRS Inability to Feel Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=26, 0, 00.5 ± 0.6NA ± NANA ± NA
Month 0; n=27, 22, 180.4 ± 0.70.2 ± 0.50.8 ± 0.8
Month 3; n=24, 22, 170.6 ± 0.90.6 ± 0.90.6 ± 1.1
Month 6; n=25, 21, 170.6 ± 1.00.4 ± 0.70.8 ± 1.3
Month 9; n=25, 20, 170.5 ± 0.80.6 ± 0.60.7 ± 1.1
Month 12; n=25, 20, 170.6 ± 0.80.4 ± 0.60.5 ± 1.1
Month 18; n=24, 19, 160.5 ± 0.80.5 ± 0.60.8 ± 1.0
Month 24; n=23, 18, 150.5 ± 0.70.6 ± 0.71.1 ± 1.4
Month 30; n=23, 17, 130.4 ± 0.60.7 ± 0.70.7 ± 0.9
Month 36; n=21, 16, 120.6 ± 0.80.5 ± 0.70.7 ± 1.4
Endpoint; n=27, 22, 170.6 ± 0.80.6 ± 0.70.9 ± 1.4
SecondaryMADRS Pessimistic Thoughts Scores From Baseline to Month 36

MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Pessimistic Thoughts scores rate thoughts of guilt, inferiority, self-reproach, sinfulness, remorse and ruin.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
MADRS Pessimistic Thoughts Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=26, 0, 00.9 ± 1.1NA ± NANA ± NA
Month 0; n=27, 22, 181.0 ± 0.80.5 ± 0.90.6 ± 0.8
Month 3; n=24, 22, 170.7 ± 0.90.5 ± 1.00.8 ± 1.0
Month 6; n=25, 21, 170.9 ± 0.90.6 ± 0.70.6 ± 0.9
Month 9; n=25, 20, 170.8 ± 0.80.5 ± 0.50.9 ± 1.0
Month 12; n=25, 20, 170.9 ± 0.80.8 ± 0.81.0 ± 0.9
Month 18; n=24, 19, 161.0 ± 0.80.7 ± 0.90.8 ± 0.8
Month 24; n=23, 18, 151.0 ± 1.00.7 ± 0.81.1 ± 0.9
Month 30; n=22, 17, 131.2 ± 0.90.7 ± 0.70.9 ± 0.8
Month 36; n=21, 16, 121.0 ± 1.00.9 ± 0.81.0 ± 1.1
Endpoint; n=26, 22, 171.2 ± 1.10.9 ± 0.81.1 ± 1.2
SecondaryMADRS Suicidal Thoughts Scores From Baseline to Month 36

MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Suicidal Thoughts scores rate the feeling that life is not worth living, that a natural death would be welcome, suicidal thoughts, and preparations for suicide.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
MADRS Suicidal Thoughts Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=26, 0, 00.4 ± 0.6NA ± NANA ± NA
Month 0; n=27, 22, 180.5 ± 1.00.2 ± 0.60.3 ± 0.7
Month 3; n=24, 22, 170.5 ± 1.10.0 ± 0.20.4 ± 0.6
Month 6; n=25, 21, 170.5 ± 1.00.1 ± 0.40.2 ± 0.4
Month 9; n=25, 20, 170.3 ± 0.70.0 ± 0.00.2 ± 0.4
Month 12; n=25, 20, 170.3 ± 0.70.3 ± 0.40.2 ± 0.7
Month 18; n=24, 19, 160.5 ± 0.90.3 ± 0.70.2 ± 0.4
Month 24; n=23, 18, 150.1 ± 0.30.2 ± 0.50.4 ± 0.8
Month 30; n=23, 17, 130.4 ± 0.80.1 ± 0.30.2 ± 0.4
Month 36; n=21, 16, 120.5 ± 1.00.1 ± 0.30.1 ± 0.3
Endpoint; n=27, 22, 170.4 ± 0.90.2 ± 0.40.4 ± 0.8
SecondaryParkinson's Disease Questionnaire-39 (PDQ-39) Summary Index Scores From Baseline to Month 36

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible, which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=27, 0, 033.6 ± 10.8NA ± NANA ± NA
Month 0; n=27, 20, 1727.1 ± 11.830.3 ± 10.736.6 ± 15.4
Month 3; n=22, 20, 1824.5 ± 10.130.0 ± 15.634.0 ± 15.2
Month 6; n=24, 20, 1727.9 ± 10.633.4 ± 16.235.5 ± 16.5
Month 9; n=23, 20, 1625.9 ± 10.630.9 ± 12.135.1 ± 15.9
Month 12; n=23, 19, 1728.8 ± 12.833.2 ± 15.538.3 ± 19.3
Month 18; n=22, 18, 1628.2 ± 12.230.4 ± 15.734.1 ± 17.0
Month 24; n=21, 17, 1430.3 ± 12.436.2 ± 14.633.6 ± 13.6
Month 30; n=21, 16, 1233.5 ± 13.134.8 ± 16.234.4 ± 17.4
Month 36; n=20, 15, 1136.8 ± 15.131.5 ± 11.539.2 ± 18.0
Endpoint; n=25, 21, 1736.2 ± 14.134.0 ± 13.640.3 ± 17.5
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 0.001 · Mean change from baseline: -6.5
  • Duodopa Naïve · Wilcoxon tests · p = <0.001 · Mean change from baseline: -9.2
  • Duodopa Naïve · Wilcoxon tests · p = 0.022 · Mean change from baseline: -5.9
  • Duodopa Naïve · Wilcoxon tests · p = 0.005 · Mean change from baseline: -7.5
  • Duodopa Naïve · Wilcoxon tests · p = 0.126 · Mean change from baseline: -5.3
  • Duodopa Naïve · Wilcoxon tests · p = 0.049 · Mean change from baseline: -5.2
  • Duodopa Naïve · Wilcoxon tests · p = 0.203 · Mean change from baseline: -3.1
  • Duodopa Naïve · Wilcoxon tests · p = 0.733 · Mean change from baseline: 0.8
  • Duodopa Naïve · Wilcoxon tests · p = 0.414 · Mean change from baseline: 4.4
  • Duodopa Naïve · Wilcoxon tests · p = 0.534 · Mean change from baseline: 2.3
SecondaryPDQ-39 Mobility Subscale Scores From Baseline to Month 36

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
PDQ-39 Mobility Subscale Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=27, 0, 055.7 ± 20.5NA ± NANA ± NA
Month 0; n=27, 22, 1838.8 ± 20.143.9 ± 21.753.3 ± 22.6
Month 3; n=23, 20, 1836.0 ± 17.640.6 ± 22.850.6 ± 24.2
Month 6; n=25, 21, 1839.5 ± 18.943.5 ± 23.554.7 ± 24.4
Month 9; n=24, 20, 1740.2 ± 15.641.9 ± 21.752.8 ± 23.0
Month 12; n=25, 20, 1741.0 ± 18.345.3 ± 24.254.4 ± 32.1
Month 18; n=24, 18, 1640.9 ± 16.241.1 ± 25.654.7 ± 29.2
Month 24; n=21, 17, 1546.0 ± 22.247.1 ± 21.549.5 ± 23.0
Month 30; n=22, 17, 1250.9 ± 21.542.1 ± 21.553.3 ± 24.8
Month 36; n=21, 15, 1157.3 ± 20.843.0 ± 21.661.1 ± 28.1
Endpoint; n=26, 21, 1755.6 ± 20.750.2 ± 22.261.6 ± 25.0
SecondaryPDQ-39 Activities of Daily Living Subscale Scores From Baseline to Month 36

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
PDQ-39 Activities of Daily Living Subscale Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=27, 0, 038.7 ± 21.5NA ± NANA ± NA
Month 0; n=27, 20, 1832.1 ± 19.040.8 ± 19.146.5 ± 26.5
Month 3; n=24, 22, 1826.9 ± 16.642.8 ± 21.841.7 ± 22.2
Month 6; n=25, 21, 1831.8 ± 18.943.7 ± 23.242.1 ± 22.5
Month 9; n=25, 20, 1729.8 ± 19.237.5 ± 18.442.2 ± 21.3
Month 12; n=25, 20, 1734.7 ± 20.842.1 ± 20.745.6 ± 26.5
Month 18; n=24, 20, 1633.2 ± 20.141.9 ± 22.945.8 ± 24.6
Month 24; n=21, 17, 1537.1 ± 22.148.3 ± 20.841.9 ± 24.1
Month 30; n=22, 17, 1238.8 ± 23.848.5 ± 19.746.5 ± 28.2
Month 36; n=21, 15, 1145.4 ± 25.147.5 ± 18.454.5 ± 29.3
Endpoint; n=26, 22, 1743.4 ± 23.348.3 ± 18.253.4 ± 24.5
SecondaryPDQ-39 Emotional Well Being Subscale Scores From Baseline to Month 36

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
PDQ-39 Emotional Well Being Subscale Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=27, 0, 035.3 ± 19.3NA ± NANA ± NA
Month 0; n=27, 22, 1830.9 ± 17.327.1 ± 19.337.7 ± 17.0
Month 3; n=23, 22, 1824.8 ± 19.527.5 ± 19.635.4 ± 21.5
Month 6; n=25, 20, 1831.3 ± 15.233.3 ± 18.635.9 ± 20.0
Month 9; n=25, 20, 1733.0 ± 18.032.1 ± 17.034.8 ± 18.6
Month 12; n=25, 20, 1729.0 ± 17.834.8 ± 20.838.0 ± 23.6
Month 18; n=24, 20, 1632.1 ± 16.230.2 ± 19.532.6 ± 22.5
Month 24; n=21, 17, 1531.9 ± 17.337.7 ± 19.033.1 ± 16.6
Month 30; n=22, 16, 1233.9 ± 16.833.3 ± 25.231.3 ± 18.2
Month 36; n=21, 15, 1139.7 ± 18.530.0 ± 21.038.6 ± 19.4
Endpoint; n=26, 22, 1739.4 ± 17.831.1 ± 24.439.7 ± 21.5
SecondaryPDQ-39 Stigma Subscale Scores From Baseline to Month 36

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
PDQ-39 Stigma Subscale Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=27, 0, 024.8 ± 15.4NA ± NANA ± NA
Month 0; n=27, 22, 1816.2 ± 16.816.5 ± 18.522.9 ± 23.0
Month 3; n=24, 22, 1816.1 ± 15.018.8 ± 23.819.8 ± 17.4
Month 6; n=25, 21, 1820.8 ± 16.219.0 ± 19.323.6 ± 24.4
Month 9; n=25, 20, 1715.5 ± 15.712.8 ± 15.124.6 ± 23.6
Month 12; n=25, 19, 1717.8 ± 17.019.4 ± 19.925.4 ± 25.5
Month 18; n=24, 20, 1615.6 ± 17.513.8 ± 15.118.8 ± 22.0
Month 24; n=21, 17, 1515.8 ± 12.423.5 ± 19.215.4 ± 14.5
Month 30; n=21, 17, 1216.4 ± 18.614.0 ± 23.618.2 ± 21.4
Month 36; n=21, 15, 1120.5 ± 19.112.9 ± 20.024.4 ± 19.3
Endpoint; n=26, 22, 1719.5 ± 18.815.6 ± 20.325.0 ± 23.8
SecondaryPDQ-39 Social Support Subscale Scores From Baseline to Month 36

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
PDQ-39 Social Support Subscale Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=27,0,08.3 ± 15.9NA ± NANA ± NA
Month 0; n=27, 22, 1710.3 ± 18.212.9 ± 14.522.1 ± 19.1
Month 3; n=24, 22, 1810.8 ± 15.212.5 ± 18.716.7 ± 19.6
Month 6; n=25, 21, 1712.7 ± 18.013.1 ± 14.124.3 ± 21.5
Month 9; n=24, 20, 1610.2 ± 16.313.8 ± 14.925.5 ± 18.1
Month 12; n=23, 20, 1712.1 ± 19.519.6 ± 19.428.4 ± 22.6
Month 18; n=22, 20, 1612.7 ± 15.617.9 ± 19.418.8 ± 18.4
Month 24; n=21, 17, 1415.7 ± 18.520.6 ± 18.721.7 ± 15.7
Month 30; n=22, 17, 1218.2 ± 24.816.2 ± 20.318.8 ± 22.8
Month 36; n=21, 15, 1118.3 ± 21.011.7 ± 13.329.5 ± 26.7
Endpoint; n=26, 22, 1721.8 ± 25.314.4 ± 18.927.9 ± 25.3
SecondaryPDQ-39 Cognition Subscale Scores From Baseline to Month 36

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
PDQ-39 Cognition Subscale Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=27, 0, 030.6 ± 15.6NA ± NANA ± NA
Month 0; n=27, 22, 1822.5 ± 13.733.0 ± 16.633.7 ± 16.9
Month 3; n=24, 22, 1824.2 ± 17.736.6 ± 18.532.3 ± 20.4
Month 6; n=24, 21, 1825.5 ± 13.737.8 ± 18.330.6 ± 16.9
Month 9; n=25, 20, 1721.5 ± 14.935.6 ± 20.031.6 ± 19.2
Month 12; n=25, 20, 1726.8 ± 20.833.1 ± 19.733.8 ± 23.2
Month 18; n=24, 20, 1628.6 ± 20.231.3 ± 22.130.1 ± 23.4
Month 24; n=21, 17, 1524.7 ± 14.741.9 ± 16.827.5 ± 19.0
Month 30; n=22, 16, 1231.5 ± 18.645.7 ± 23.730.7 ± 24.6
Month 36; n=20, 15, 1134.1 ± 19.442.1 ± 16.630.7 ± 19.7
Endpoint; n=25, 22, 1731.5 ± 19.839.2 ± 20.234.9 ± 19.5
SecondaryPDQ-39 Communication Subscale Scores From Baseline to Month 36

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
PDQ-39 Communication Subscale Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=27, 0, 032.4 ± 21.6NA ± NANA ± NA
Month 0; n=27, 22, 1824.1 ± 18.727.3 ± 14.635.2 ± 18.4
Month 3; n=24, 22, 1824.7 ± 20.332.2 ± 22.231.9 ± 19.9
Month 6; n=24, 21, 1824.0 ± 17.132.5 ± 22.033.8 ± 19.3
Month 9; n=25, 20, 1725.3 ± 23.331.7 ± 17.228.9 ± 21.3
Month 12; n=25, 20, 1729.7 ± 20.134.2 ± 18.333.8 ± 16.0
Month 18; n=24, 20, 1631.6 ± 21.832.1 ± 19.029.7 ± 20.4
Month 24; n=21, 17, 1528.2 ± 19.634.8 ± 18.230.6 ± 19.1
Month 30; n=22, 17, 1233.7 ± 22.637.7 ± 18.441.7 ± 26.6
Month 36; n=21, 15, 1133.7 ± 20.733.3 ± 13.037.9 ± 19.1
Endpoint; n=26, 22, 1734.0 ± 20.933.0 ± 15.540.2 ± 18.7
SecondaryPDQ-39 Bodily Discomfort Subscale Scores From Baseline to Month 36

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
PDQ-39 Bodily Discomfort Subscale Scores From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Baseline (Month -3); n=27, 0, 042.6 ± 19.8NA ± NANA ± NA
Month 0; n=27, 22, 1841.7 ± 18.340.2 ± 17.643.1 ± 24.8
Month 3; n=24, 22, 1838.5 ± 21.739.8 ± 20.744.0 ± 21.4
Month 6; n=24, 21, 1838.9 ± 22.142.1 ± 20.539.4 ± 23.2
Month 9; n=25, 20, 1736.3 ± 18.842.1 ± 23.641.2 ± 24.7
Month 12; n=25, 20, 1739.3 ± 21.034.6 ± 20.146.6 ± 27.6
Month 18; n=24, 20, 1638.5 ± 23.537.1 ± 20.742.7 ± 24.5
Month 24; n=21, 17, 1542.9 ± 24.235.3 ± 25.838.9 ± 23.7
Month 30; n=22, 17, 1242.8 ± 23.339.2 ± 24.834.7 ± 27.3
Month 36; n=21, 15, 1142.9 ± 17.931.7 ± 15.837.1 ± 20.2
Endpoint; n=26, 22, 1742.6 ± 19.236.7 ± 20.539.7 ± 24.6
SecondaryElectronic Diary: Morning and Day Scores (Walking) From Baseline to Month 36

The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Walking scores ranged from 1 (worst) to 5 (best).

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
Electronic Diary: Morning and Day Scores (Walking) From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Morning, Baseline (Month -3); n=20, 0, 02.7 ± 1.2NA ± NANA ± NA
Day, Baseline (Month -3); n=20, 0, 03.1 ± 0.9NA ± NANA ± NA
Morning, Month 0; n=19, 20, 153.3 ± 1.43.2 ± 1.13.4 ± 1.0
Day, Month 0; n=19, 20, 153.7 ± 1.13.7 ± 0.83.3 ± 1.0
Morning, Month 3; n=19, 19, 133.5 ± 1.13.0 ± 1.13.1 ± 1.0
Day, Month 3; n=19, 19, 133.7 ± 0.83.6 ± 1.03.3 ± 0.9
Morning, Month 6; n=16, 19, 113.5 ± 1.23.2 ± 1.13.3 ± 1.1
Day, Month 6; n=16, 19, 114.0 ± 0.73.7 ± 0.93.4 ± 0.9
Morning, Month 9; n=16, 17, 93.6 ± 1.03.3 ± 1.03.1 ± 1.3
Day, Month 9; n=16, 17, 94.0 ± 0.43.8 ± 0.93.1 ± 1.2
Morning, Month 12; n=16, 16, 93.6 ± 1.23.5 ± 1.13.1 ± 1.3
Day, Month 12; n=16, 16, 93.7 ± 1.03.8 ± 1.13.1 ± 1.2
Morning, Month 18; n=15, 14, 103.3 ± 1.23.5 ± 1.03.4 ± 1.1
Day, Month 18; n=15, 14, 103.8 ± 0.83.9 ± 0.83.5 ± 1.1
Morning, Month 24; n=14, 13, 73.4 ± 1.13.5 ± 1.02.9 ± 1.3
Day, Month 24; n=13, 13, 73.9 ± 0.43.9 ± 0.92.8 ± 1.5
Morning, Month 30; n=9, 9, 53.4 ± 1.33.4 ± 1.03.6 ± 0.9
Day, Month 30; n=9, 9, 53.8 ± 0.74.0 ± 0.53.9 ± 0.5
Morning, Month 36; n=6, 11, 52.3 ± 1.33.6 ± 1.03.7 ± 0.9
Day, Month 36; n=5, 11, 53.1 ± 1.34.0 ± 1.03.7 ± 0.6
Morning, Endpoint; n=23, 20, 162.8 ± 1.23.4 ± 1.03.0 ± 1.0
Day, Endpoint; n=23, 20, 163.4 ± 1.03.8 ± 0.93.0 ± 1.1
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 0.016
  • Duodopa Naïve · Wilcoxon tests · p = 0.188
SecondaryElectronic Diary: Morning and Day Scores (Off Time) From Baseline to Month 36

The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. "Off" time is when PD symptoms are not adequately controlled by the drug, and is represented as a percentage of total time awake per day.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · percentage of 'off' time
Electronic Diary: Morning and Day Scores (Off Time) From Baseline to Month 36
percentage of 'off' timeDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Morning, Baseline (Month -3); n=20, 0, 041.2 ± 19.4NA ± NANA ± NA
Day, Baseline (Month -3); n=20, 0, 035.4 ± 11.7NA ± NANA ± NA
Morning, Month 0; n=19, 20, 1523.4 ± 19.730.6 ± 21.225.1 ± 12.7
Day, Month 0; n=19, 20, 1520.8 ± 14.621.4 ± 9.225.7 ± 12.3
Morning, Month 3; n=19, 18, 1326.4 ± 20.234.3 ± 20.025.7 ± 18.8
Day, Month 3; n=19, 19, 1323.0 ± 12.822.7 ± 13.920.2 ± 10.3
Morning, Month 6; n=16, 19, 1125.6 ± 21.030.1 ± 21.118.6 ± 10.9
Day, Month 6; n=16, 19, 1121.9 ± 13.321.8 ± 15.320.9 ± 10.7
Morning, Month 9; n=16, 17, 923.9 ± 18.432.3 ± 20.523.6 ± 15.6
Day, Month 9; n=16, 17, 919.5 ± 13.421.5 ± 10.822.8 ± 11.6
Morning, Month 12; n=16, 16, 925.3 ± 17.828.0 ± 23.323.8 ± 16.0
Day, Month 12; n=16, 16, 924.0 ± 17.319.5 ± 16.023.5 ± 9.0
Morning, Month 18; n=15, 14, 1021.1 ± 13.028.9 ± 21.424.9 ± 16.2
Day, Month 18; n=15, 14, 1017.9 ± 8.621.6 ± 13.820.1 ± 11.9
Morning, Month 24; n=13, 13, 729.1 ± 21.625.4 ± 16.030.4 ± 17.9
Day, Month 24; n=13, 13, 722.0 ± 15.521.3 ± 14.224.9 ± 12.2
Morning, Month 30; n=9, 9, 523.4 ± 19.829.4 ± 23.128.0 ± 16.8
Day, Month 30; n=9, 9, 521.6 ± 15.124.0 ± 13.423.0 ± 11.2
Morning, Month 36; n=6, 11, 535.1 ± 25.229.4 ± 23.331.5 ± 15.1
Day, Month 36; n=5, 11, 524.7 ± 19.418.8 ± 11.723.6 ± 12.2
Morning, Endpoint; n=23, 20, 1630.7 ± 22.828.5 ± 21.427.1 ± 13.8
Day, Endpoint; n=23, 20, 1624.8 ± 17.222.3 ± 14.225.9 ± 11.7
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 0.008
  • Duodopa Naïve · Wilcoxon tests · p = 0.107
SecondaryElectronic Diary: Morning and Day Scores (On Time) From Baseline to Month 36

The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. "On" time is when PD symptoms are well controlled by the drug, and is represented as a percentage of total time of the last __ hours.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · percentage of 'on' time
Electronic Diary: Morning and Day Scores (On Time) From Baseline to Month 36
percentage of 'on' timeDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Morning, Baseline (Month -3); n=20, 0, 040.2 ± 16.7NA ± NANA ± NA
Day, Baseline (Month -3); n=20, 0, 040.3 ± 14.0NA ± NANA ± NA
Morning, Month 0; n=19, 20, 1558.4 ± 28.049.8 ± 23.155.2 ± 27.1
Day, Month 0; n=19, 20, 1561.8 ± 19.860.2 ± 14.846.5 ± 28.0
Morning, Month 3; n=19, 18, 1361.6 ± 23.652.0 ± 22.849.8 ± 28.2
Day, Month 3; n=19, 19, 1362.6 ± 17.858.3 ± 20.755.0 ± 26.4
Morning, Month 6; n=16, 19, 1157.7 ± 28.455.5 ± 24.155.8 ± 31.1
Day, Month 6; n=16, 19, 1162.2 ± 22.057.3 ± 21.353.2 ± 29.7
Morning, Month 9; n=16, 17, 960.5 ± 25.152.3 ± 25.447.9 ± 29.4
Day, Month 9; n=16, 17, 959.7 ± 23.459.5 ± 18.150.8 ± 29.2
Morning, Month 12; n=16, 16, 961.1 ± 23.557.5 ± 23.449.0 ± 32.2
Day, Month 12; n=16, 16, 959.5 ± 25.063.0 ± 21.951.4 ± 26.9
Morning, Month 18; n=15, 14, 1061.9 ± 21.455.2 ± 27.151.1 ± 33.4
Day, Month 18; n=15, 14, 1061.5 ± 17.957.6 ± 20.752.5 ± 31.3
Morning, Month 24; n=13, 13, 761.3 ± 25.859.5 ± 23.141.3 ± 22.0
Day, Month 24; n=13, 13, 762.3 ± 21.757.4 ± 23.842.7 ± 24.8
Morning, Month 30; n=9, 9, 564.8 ± 28.349.3 ± 27.558.6 ± 26.3
Day, Month 30; n=9, 9, 562.4 ± 27.356.9 ± 20.158.8 ± 26.6
Morning, Month 36; n=6, 11, 554.5 ± 16.855.3 ± 23.451.9 ± 26.8
Day, Month 36; n=5, 11, 559.1 ± 14.861.8 ± 18.855.1 ± 28.2
Morning, Endpoint; n=23, 20, 1652.9 ± 26.254.6 ± 21.849.9 ± 23.5
Day, Endpoint; n=23, 20, 1656.0 ± 21.256.5 ± 18.046.2 ± 25.7
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 0.002
  • Duodopa Naïve · Wilcoxon tests · p = 0.010
SecondaryElectronic Diary: Morning and Day Scores (Dyskinetic Time) From Baseline to Month 36

The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Dyskinetic time' is time with involuntary muscle movement, and is represented as a percentage of total time of the last __ hours.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · percentage of 'dyskinetic' time
Electronic Diary: Morning and Day Scores (Dyskinetic Time) From Baseline to Month 36
percentage of 'dyskinetic' timeDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Morning, Baseline (Month -3); n=20, 0, 018.6 ± 12.4NA ± NANA ± NA
Day, Baseline (Month -3); n=20, 0, 024.3 ± 14.4NA ± NANA ± NA
Morning, Month 0; n=19, 20, 1518.2 ± 24.219.6 ± 17.819.7 ± 17.5
Day, Month 0; n=19, 20, 1517.4 ± 14.518.4 ± 12.527.3 ± 19.7
Morning, Month 3; n=19, 18, 1312.0 ± 12.013.7 ± 13.624.5 ± 20.0
Day, Month 3; n=19, 19, 1314.4 ± 13.018.9 ± 16.524.8 ± 21.3
Morning, Month 6; n=16, 19, 1116.7 ± 17.314.4 ± 12.925.6 ± 24.3
Day, Month 6; n=16, 19, 1115.9 ± 15.420.8 ± 16.325.8 ± 22.9
Morning, Month 9; n=16, 17, 915.6 ± 13.915.5 ± 9.428.5 ± 28.0
Day, Month 9; n=16, 17, 920.8 ± 15.419.0 ± 12.026.5 ± 22.8
Morning, Month 12; n=16, 16, 913.6 ± 13.214.6 ± 10.427.2 ± 24.8
Day, Month 12; n=16, 16, 916.2 ± 13.517.4 ± 13.825.1 ± 21.1
Morning, Month 18; n=15, 14, 1017.0 ± 14.515.9 ± 11.624.0 ± 22.6
Day, Month 18; n=15, 14, 1020.6 ± 11.920.8 ± 11.027.4 ± 21.2
Morning, Month 24; n=13, 13, 79.6 ± 12.015.0 ± 11.928.2 ± 19.5
Day, Month 24; n=13, 13, 715.8 ± 12.721.3 ± 19.032.4 ± 17.6
Morning, Month 30; n=9, 9, 511.8 ± 20.221.3 ± 15.213.4 ± 14.8
Day, Month 30; n=9, 9, 514.5 ± 16.819.1 ± 12.118.2 ± 16.9
Morning, Month 36; n=6, 11, 510.4 ± 9.815.2 ± 10.316.6 ± 18.0
Day, Month 36; n=5, 11, 516.2 ± 9.319.4 ± 10.821.3 ± 21.1
Morning, Endpoint; n=23, 20, 1616.5 ± 21.416.9 ± 11.623.0 ± 15.5
Day, Endpoint; n=23, 20, 1616.2 ± 9.319.4 ± 10.821.3 ± 21.1
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 0.048
  • Duodopa Naïve · Wilcoxon tests · p = 0.003
SecondaryElectronic Diary: Morning and Day Scores (Off Magnitude) From Baseline to Month 36

The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Off time' is when PD symptoms are not adequately controlled by the drug. Magnitude scores were 1 (worst) to 5 (best).

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
Electronic Diary: Morning and Day Scores (Off Magnitude) From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Morning, Baseline (Month -3); n=20, 0, 02.7 ± 0.8NA ± NANA ± NA
Day, Baseline (Month -3); n=20, 0, 02.8 ± 0.5NA ± NANA ± NA
Morning, Month 0; n=19, 20, 153.6 ± 0.93.2 ± 0.93.4 ± 0.7
Day, Month 0; n=19, 20, 153.6 ± 0.73.5 ± 0.63.3 ± 0.6
Morning, Month 3; n=19, 18, 133.5 ± 0.82.8 ± 0.93.1 ± 0.9
Day, Month 3; 19, 19, 133.6 ± 0.53.6 ± 0.73.3 ± 0.6
Morning, Month 6; n=16, 19, 113.4 ± 0.93.2 ± 0.93.7 ± 0.6
Day, Month 6; 16, 19, 113.8 ± 0.53.7 ± 0.63.4 ± 0.6
Morning, Month 9; n=16, 17, 93.7 ± 0.83.3 ± 0.83.3 ± 0.5
Day, Month 9; n=16, 17, 93.8 ± 0.53.6 ± 0.73.2 ± 0.6
Morning, Month 12; n=16, 16, 93.7 ± 0.83.3 ± 1.03.4 ± 0.6
Day, Month 12; n=16, 16, 93.6 ± 0.73.6 ± 0.93.4 ± 0.6
Morning, Month 18; n=15, 14, 103.7 ± 0.73.3 ± 1.03.2 ± 0.7
Day, Month 18; n=15, 14, 103.8 ± 0.63.7 ± 0.73.5 ± 0.7
Morning, Month 24; n=13, 13, 73.6 ± 0.93.5 ± 0.83.1 ± 0.6
Day, Month 24; n=13, 13, 73.7 ± 0.73.6 ± 0.73.4 ± 0.6
Morning, Month 30; n=9, 9, 53.8 ± 0.93.3 ± 0.92.9 ± 0.7
Day, Month 30; n=9, 9, 53.8 ± 0.83.6 ± 0.73.2 ± 0.6
Morning, Month 36; n=6, 11, 53.1 ± 1.23.5 ± 0.83.2 ± 0.4
Day, Month 36; n=5, 11, 53.5 ± 0.83.8 ± 0.63.0 ± 0.8
Morning, Endpoint; n=23, 20, 163.3 ± 0.93.4 ± 0.83.3 ± 0.8
Day, Endpoint; n=23, 20, 163.5 ± 0.73.6 ± 0.63.1 ± 0.7
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 0.001
  • Duodopa Naïve · Wilcoxon tests · p = 0.003
SecondaryElectronic Diary: Morning and Day Scores (Dyskinetic Magnitude) From Baseline to Month 36

The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Dyskinetic time' is time with involuntary muscle movement. Magnitude scores were 1 (worst) to 5 (best).

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
Electronic Diary: Morning and Day Scores (Dyskinetic Magnitude) From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Morning, Baseline (Month -3); n=20, 0, 04.1 ± 0.8NA ± NANA ± NA
Day, Baseline (Month -3); n=20, 0, 03.6 ± 0.7NA ± NANA ± NA
Morning, Month 0; n=19, 20, 154.1 ± 0.84.1 ± 0.84.0 ± 0.6
Day, Month 0; n=19, 20, 154.0 ± 0.74.0 ± 0.53.7 ± 0.8
Morning, Month 3; n=19, 18, 134.4 ± 0.64.2 ± 0.54.0 ± 0.7
Day, Month 3; n=19, 19, 134.2 ± 0.64.0 ± 0.63.7 ± 0.8
Morning, Month 6; n=16, 19, 114.1 ± 0.64.1 ± 0.83.9 ± 0.7
Day, Month 6; n=16, 19, 114.2 ± 0.63.8 ± 0.83.7 ± 0.8
Morning, Month 9; n=16, 17, 94.1 ± 0.74.2 ± 0.63.7 ± 0.8
Day, Month 9; n=16, 17, 93.8 ± 0.74.0 ± 0.63.8 ± 0.6
Morning, Month 12; n=16, 16, 94.1 ± 0.64.2 ± 0.63.7 ± 0.7
Day, Month 12; n=16, 16, 94.1 ± 0.63.7 ± 0.83.8 ± 0.7
Morning, Month 18; n=15, 14, 103.9 ± 0.63.8 ± 0.73.9 ± 0.7
Day, Month 18; n=15, 14, 103.9 ± 0.53.9 ± 0.43.8 ± 0.8
Morning, Month 24; n=13, 13, 74.4 ± 0.64.2 ± 0.64.1 ± 0.6
Day, Month 24; n=13, 13, 74.1 ± 0.63.9 ± 0.63.8 ± 0.5
Morning, Month 30; n=9, 9, 54.5 ± 0.73.9 ± 0.64.2 ± 0.7
Day, Month 30; n=9, 9, 54.5 ± 0.53.9 ± 0.64.1 ± 0.6
Morning, Month 36; n=6, 11, 54.3 ± 0.84.0 ± 0.74.1 ± 0.6
Day, Month 36; n=5, 11, 54.0 ± 0.53.7 ± 0.64.0 ± 0.7
Morning, Endpoint; n=23, 20, 164.3 ± 0.84.0 ± 0.74.1 ± 0.6
Day, Endpoint; 23, 20, 164.0 ± 0.73.7 ± 0.63.6 ± 0.8
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 1.000
  • Duodopa Naïve · Wilcoxon tests · p = 0.002
SecondaryElectronic Diary: Morning and Day Scores (Cramps) From Baseline to Month 36

The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Cramps' scores were 1 (worst) to 5 (best).

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
Electronic Diary: Morning and Day Scores (Cramps) From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Morning, Baseline (Month -3); n=20, 0, 04.4 ± 0.7NA ± NANA ± NA
Day, Baseline (Month -3); n=20, 0, 04.5 ± 0.6NA ± NANA ± NA
Morning, Month 0; n=19, 20, 154.7 ± 0.44.6 ± 0.74.6 ± 0.4
Day, Month 0; n=19, 20, 154.7 ± 0.44.7 ± 0.54.6 ± 0.5
Morning, Month 3; n=19, 18, 134.8 ± 0.34.6 ± 0.74.5 ± 0.6
Day, Month 3; n=19, 19, 134.7 ± 0.54.7 ± 0.64.5 ± 0.7
Morning, Month 6; n=16, 19, 114.8 ± 0.34.5 ± 0.94.3 ± 1.2
Day, Month 6; n=16, 19, 114.8 ± 0.34.5 ± 0.84.3 ± 1.1
Morning, Month 9; n=16, 17, 94.8 ± 0.34.4 ± 0.74.4 ± 1.0
Day, Month 9; n=16, 17, 94.7 ± 0.54.5 ± 0.74.3 ± 0.9
Morning, Month 12; n=16, 16, 94.8 ± 0.34.5 ± 0.74.2 ± 1.4
Day, Month 12; n=16, 16, 94.5 ± 0.74.7 ± 0.54.1 ± 1.3
Morning, Month 18; n=15, 14, 104.7 ± 0.44.4 ± 0.84.1 ± 0.8
Day, Month 18; n=15, 14, 104.7 ± 0.54.6 ± 0.54.3 ± 1.0
Morning, Month 24; n=13, 13, 74.6 ± 0.44.8 ± 0.24.0 ± 1.4
Day, Month 24; n=13, 13, 74.5 ± 0.64.8 ± 0.34.0 ± 1.3
Morning, Month 30; n=9, 9, 54.9 ± 0.34.7 ± 0.44.1 ± 1.5
Day, Month 30; n=9, 9, 54.9 ± 0.34.8 ± 0.23.9 ± 1.5
Morning, Month 36; n=6, 11, 54.5 ± 0.44.7 ± 0.34.1 ± 1.3
Day, Month 36; n=5, 11, 54.7 ± 0.64.8 ± 0.24.2 ± 1.0
Morning, Endpoint; n=23, 20, 164.6 ± 0.44.5 ± 0.74.4 ± 0.8
Day, Endpoint; n=23, 20, 164.5 ± 0.64.6 ± 0.54.5 ± 0.7
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 0.017
  • Duodopa Naïve · Wilcoxon tests · p = 0.191
SecondaryElectronic Diary: Morning and Day Scores (Satisfied With Function) From Baseline to Month 36

The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Satisfied with function' scores were 1 (worst) to 5 (best).

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
Electronic Diary: Morning and Day Scores (Satisfied With Function) From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Morning, Baseline (Month -3); n=20, 0, 02.5 ± 1.0NA ± NANA ± NA
Day, Baseline (Month -3); n=20, 0, 02.6 ± 0.5NA ± NANA ± NA
Morning, Month 0; n=19, 20, 153.3 ± 0.93.2 ± 0.93.8 ± 0.8
Day, Month 0; n=19, 20, 153.4 ± 0.73.4 ± 0.63.3 ± 1.0
Morning, Month 3; n=19, 18, 133.4 ± 0.93.0 ± 1.13.4 ± 1.1
Day, Month 3; n=19, 19, 133.5 ± 0.63.4 ± 0.83.3 ± 0.9
Morning, Month 6; n=16, 19, 113.5 ± 0.93.3 ± 0.83.7 ± 0.8
Day, Month 6; n=16, 19, 113.6 ± 0.63.4 ± 0.73.5 ± 0.7
Morning, Month 9; n=16, 17, 93.4 ± 0.73.3 ± 0.93.6 ± 0.7
Day, Month 9; n=16, 17, 93.5 ± 0.63.4 ± 0.83.4 ± 0.7
Morning, Month 12; n=16, 16, 93.6 ± 0.83.4 ± 0.83.5 ± 0.8
Day, Month 12; n=16, 16, 93.5 ± 0.63.6 ± 0.63.6 ± 0.7
Morning, Month 18; n=15, 14, 103.4 ± 0.93.4 ± 0.83.3 ± 1.1
Day, Month 18; n=15, 14, 103.5 ± 0.63.6 ± 0.53.4 ± 0.8
Morning, Month 24; n=13, 13, 73.4 ± 0.93.6 ± 0.73.1 ± 0.9
Day, Month 24; n=13, 13, 73.6 ± 0.63.5 ± 0.73.3 ± 0.9
Morning, Month 30; n=9, 9, 53.6 ± 0.83.4 ± 0.93.6 ± 0.9
Day, Month 30; n=9, 9, 53.5 ± 0.83.6 ± 0.53.6 ± 0.5
Morning, Month 36; n=6, 11, 53.4 ± 0.43.3 ± 0.83.5 ± 0.9
Day, Month 36; n=5, 11, 53.5 ± 0.53.5 ± 0.73.5 ± 0.8
Morning, Endpoint; n=23, 20, 163.2 ± 0.73.3 ± 0.73.4 ± 0.9
Day, Endpoint; n=23, 20, 163.4 ± 0.63.4 ± 0.63.1 ± 0.9
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 0.002
  • Duodopa Naïve · Wilcoxon tests · p = <0.001
SecondaryElectronic Diary: Morning and Day Scores (Self-assessment) From Baseline to Month 36

The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Self-assessment' scores were -3 (Off) to +3 (dyskinetic). 'Off' time is when PD symptoms are not adequately controlled by the drug. 'Dyskinetic' time is time with involuntary muscle movement. "0" is defined as the normal ON state without dyskinesia (the desired motor state). Everything closer to "0" means improvement, everything more away from "0" means either less mobility (in the negative score) or involuntary movements (dyskinesia, in the positive score).

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
Electronic Diary: Morning and Day Scores (Self-assessment) From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Morning, Baseline (Month -3); n=20, 0, 0-0.9 ± 1.2NA ± NANA ± NA
Day, Baseline (Month -3); n=20, 0, 0-0.3 ± 1.1NA ± NANA ± NA
Morning, Month 0; n=19, 20, 15-0.4 ± 1.1-0.1 ± 1.00.2 ± 0.8
Day, Month 0; n=19, 20, 15-0.2 ± 0.9-0.1 ± 0.60.1 ± 1.0
Morning, Month 3; n=19, 18, 13-0.2 ± 0.9-0.6 ± 0.90.0 ± 0.8
Day, Month 3; n=19, 19, 13-0.3 ± 0.7-0.1 ± 0.70.3 ± 1.0
Morning, Month 6; n=16, 19, 11-0.4 ± 1.0-0.2 ± 1.00.3 ± 0.7
Day, Month 6; n=16, 19, 11-0.2 ± 0.80.0 ± 0.80.3 ± 0.7
Morning, Month 9; n=16, 17, 9-0.2 ± 0.8-0.4 ± 0.70.4 ± 1.0
Day, Month 9; n=16, 17, 90.2 ± 0.8-0.0 ± 0.5-0.1 ± 0.6
Morning, Month 12; n=16, 16, 9-0.3 ± 0.8-0.2 ± 0.90.4 ± 0.6
Day, Month 12; n=16, 16, 9-0.3 ± 0.90.1 ± 0.80.1 ± 0.8
Morning, Month 18; n=15, 14, 10-0.3 ± 0.80.1 ± 0.8-0.0 ± 0.9
Day, Month 18; n=15, 14, 10-0.2 ± 0.7-0.2 ± 0.40.1 ± 0.9
Morning, Month 24; n=13, 13, 7-0.5 ± 0.8-0.0 ± 0.70.1 ± 0.9
Day, Month 24; n=13, 13, 7-0.2 ± 0.8-0.1 ± 0.8-0.0 ± 0.5
Morning, Month 30; n=9, 9, 5-0.4 ± 1.2-0.2 ± 0.90.2 ± 1.1
Day, Month 30; n=9, 9, 5-0.3 ± 0.8-0.3 ± 0.5-0.3 ± 0.5
Morning, Month 36; n=6, 11, 5-0.9 ± 1.3-0.0 ± 1.20.3 ± 0.7
Day, Month 36; n=5, 11, 5-0.2 ± 1.00.2 ± 0.5-0.2 ± 0.8
Morning, Endpoint; n=23, 20, 16-0.6 ± 1.1-0.2 ± 1.10.2 ± 0.7
Day, Endpoint; n=23, 20, 16-0.3 ± 1.0-0.0 ± 0.70.2 ± 1.0
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 0.047
  • Duodopa Naïve · Wilcoxon tests · p = 0.847
SecondaryElectronic Diary: Morning and Day Scores (Free Tapping - Speed) From Baseline to Month 36

The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Free tapping is defined as voluntary repetitive finger tapping on computer-generated fields. 'Free tapping speed' is a count of the number of taps per 20 seconds.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · taps/20 seconds
Electronic Diary: Morning and Day Scores (Free Tapping - Speed) From Baseline to Month 36
taps/20 secondsDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Morning, Baseline (Month -3); n=20, 0, 039.9 ± 12.8NA ± NANA ± NA
Day, Baseline (Month -3); n=20, 0, 039.7 ± 11.2NA ± NANA ± NA
Morning, Month 0; n=19, 20, 1544.4 ± 12.539.2 ± 14.240.6 ± 14.1
Day, Month 0; n=19, 20, 1543.5 ± 11.540.2 ± 12.540.3 ± 13.0
Morning, Month 3; n=19, 18, 1346.8 ± 15.142.2 ± 15.646.3 ± 13.6
Day, Month 3; n=19, 19, 1347.4 ± 13.843.2 ± 14.543.2 ± 12.9
Morning, Month 6; n=16, 19, 1150.7 ± 15.543.4 ± 17.548.0 ± 14.3
Day, Month 6; n=16, 19, 1150.3 ± 14.943.0 ± 15.847.6 ± 12.0
Morning, Month 9; n=16, 17, 947.2 ± 13.345.7 ± 20.046.8 ± 16.0
Day, Month 9; n=16, 17, 948.1 ± 15.748.0 ± 16.847.0 ± 15.3
Morning, Month 12; n=16, 16, 949.3 ± 16.044.5 ± 16.147.0 ± 18.8
Day, Month 12; n=16, 16, 948.7 ± 17.646.6 ± 15.146.6 ± 18.5
Morning, Month 18; n=15, 14, 1044.0 ± 14.143.1 ± 17.546.7 ± 18.9
Day, Month 18; n=15, 14, 1046.9 ± 12.546.3 ± 15.145.9 ± 18.1
Morning, Month 24; n=13, 13, 747.3 ± 14.945.5 ± 17.638.7 ± 14.7
Day, Month 24; n=13, 13, 747.6 ± 15.048.7 ± 14.241.5 ± 12.9
Morning, Month 30; n=9, 9, 549.4 ± 15.742.2 ± 18.149.3 ± 22.5
Day, Month 30; n=9, 9, 549.5 ± 13.042.6 ± 16.152.6 ± 19.1
Morning, Month 36; n=6, 11, 546.3 ± 14.044.7 ± 18.651.4 ± 25.0
Day, Month 36; n=5, 11, 545.5 ± 8.545.6 ± 19.750.5 ± 23.6
Morning, Endpoint; n=23, 20, 1641.8 ± 11.641.2 ± 16.843.1 ± 16.8
Day, Endpoint; n=23, 20, 1643.6 ± 12.143.2 ± 16.641.4 ± 15.0
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 0.012
  • Duodopa Naïve · Wilcoxon tests · p = 0.035
SecondaryElectronic Diary: Morning and Day Scores (Free Tapping - Accuracy) From Baseline to Month 36

The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Free tapping' is defined as ____. 'Free tapping accuracy' is the percentage of accurate free taps per 20 seconds(?).

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · percentage of tapping accuracy
Electronic Diary: Morning and Day Scores (Free Tapping - Accuracy) From Baseline to Month 36
percentage of tapping accuracyDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Morning, Baseline (Month -3); n=20, 0, 070.7 ± 16.4NA ± NANA ± NA
Day, Baseline (Month -3); n=20, 0, 071.9 ± 14.2NA ± NANA ± NA
Morning, Month 0; n=19, 20, 1571.4 ± 16.269.8 ± 13.863.8 ± 13.1
Day, Month 0; n=19, 20, 1570.1 ± 14.670.7 ± 12.465.2 ± 10.1
Morning, Month 3; n=19, 18, 1373.4 ± 13.070.3 ± 13.963.5 ± 13.4
Day, Month 3; n=19, 19, 1370.0 ± 14.469.7 ± 12.465.8 ± 12.9
Morning, Month 6; n=16, 19, 1167.6 ± 9.466.2 ± 13.864.8 ± 17.2
Day, Month 6; n=16, 19, 1165.7 ± 13.066.1 ± 12.666.7 ± 14.1
Morning, Month 9; n=16, 17, 967.0 ± 13.363.6 ± 16.965.8 ± 14.2
Day, Month 9; n=16, 17, 965.4 ± 9.369.9 ± 13.467.5 ± 10.9
Morning, Month 12; n=16, 16, 968.7 ± 15.371.5 ± 14.461.5 ± 8.8
Day, Month 12; n=16, 16, 964.7 ± 16.971.7 ± 11.960.4 ± 9.1
Morning, Month 18; n=15, 14, 1058.9 ± 10.865.4 ± 18.265.8 ± 13.3
Day, Month 18; n=15, 14, 1061.2 ± 11.069.1 ± 12.361.4 ± 12.7
Morning, Month 24; n=13, 13, 762.3 ± 16.966.2 ± 16.761.9 ± 14.3
Day, Month 24; n=13, 13, 764.4 ± 14.569.1 ± 15.962.4 ± 11.7
Morning, Month 30; n=9, 9, 566.3 ± 10.667.2 ± 12.862.1 ± 13.6
Day, Month 30; n=9, 9, 566.8 ± 12.167.3 ± 12.367.9 ± 10.5
Morning, Month 36; n=6, 11, 560.7 ± 24.160.3 ± 19.361.2 ± 12.6
Day, Month 36; n=5, 11, 550.3 ± 13.064.6 ± 15.563.6 ± 11.2
Morning, Endpoint; n=23, 20, 1663.7 ± 17.158.7 ± 17.059.3 ± 13.6
Day, Endpoint; n=23, 20, 1660.1 ± 15.862.7 ± 14.760.3 ± 13.7
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 0.599
  • Duodopa Naïve · Wilcoxon tests · p = 0.048
SecondaryElectronic Diary: Morning and Day Scores (Tapping, Increased Speed - Accuracy) From Baseline to Month 36

The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. 'Tapping at increased speed - accuracy' is the percentage of accurate taps per all taps on computer-generated fields.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · percentage of accurate taps
Electronic Diary: Morning and Day Scores (Tapping, Increased Speed - Accuracy) From Baseline to Month 36
percentage of accurate tapsDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Morning, Baseline (Month -3); n=20, 0, 074.6 ± 13.9NA ± NANA ± NA
Day, Baseline (Month -3); n=20, 0, 073.7 ± 14.7NA ± NANA ± NA
Morning, Month 0; n=19, 20, 1583.7 ± 12.071.0 ± 24.873.2 ± 15.1
Day, Month 0; n=19, 20, 1580.4 ± 10.673.9 ± 18.673.2 ± 13.8
Morning, Month 3; n=19, 18, 1383.1 ± 14.873.5 ± 22.368.8 ± 22.7
Day, Month 3; n=19, 19, 1381.3 ± 14.574.7 ± 20.569.3 ± 20.2
Morning, Month 6; n=16, 19, 1187.1 ± 11.074.2 ± 22.173.3 ± 20.1
Day, Month 6; n=16, 19, 1187.8 ± 9.873.6 ± 20.373.0 ± 21.2
Morning, Month 9; n=16, 17, 986.4 ± 11.178.2 ± 19.077.1 ± 16.9
Day, Month 9; n=16, 17, 986.0 ± 10.178.8 ± 15.375.6 ± 19.0
Morning, Month 12; n=16, 16, 987.0 ± 12.580.1 ± 18.674.6 ± 20.0
Day, Month 12; n=16, 16, 981.8 ± 15.677.5 ± 20.972.4 ± 23.6
Morning, Month 18; n=15, 14, 1081.3 ± 13.977.9 ± 18.571.4 ± 25.8
Day, Month 18; n=15, 14, 1082.1 ± 12.978.7 ± 19.272.1 ± 24.4
Morning, Month 24; n=13, 13, 785.7 ± 13.179.4 ± 20.669.0 ± 18.9
Day, Month 24; n=13, 13, 785.3 ± 10.682.0 ± 15.970.0 ± 16.9
Morning, Month 30; n=9, 9, 587.3 ± 5.173.5 ± 21.179.8 ± 18.1
Day, Month 30; n=9, 9, 588.6 ± 6.474.5 ± 19.780.6 ± 20.5
Morning, Month 36; n=6, 11, 577.9 ± 18.871.7 ± 24.981.0 ± 17.3
Day, Month 36; n=5, 11, 570.7 ± 15.972.8 ± 21.877.9 ± 21.1
Morning, Endpoint; n=23, 20, 1679.5 ± 17.770.4 ± 23.868.0 ± 19.7
Day, Endpoint; n=23, 20, 1674.6 ± 17.472.0 ± 22.267.5 ± 20.5
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 0.026
  • Duodopa Naïve · Wilcoxon tests · p = 0.208
SecondaryElectronic Diary: Morning and Day Scores (Tapping, Random Chase - Speed) From Baseline to Month 36

The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Tapping: Random chase speed' is defined as the number of correct taps of fields randomly selected by the computer per 20 seconds.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · taps/20 seconds
Electronic Diary: Morning and Day Scores (Tapping, Random Chase - Speed) From Baseline to Month 36
taps/20 secondsDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Morning, Baseline (Month -3); n=20, 0, 024.5 ± 4.1NA ± NANA ± NA
Day, Baseline (Month -3); n=20, 0, 024.2 ± 4.2NA ± NANA ± NA
Morning, Month 0; n=19, 20, 1526.3 ± 4.822.6 ± 5.822.7 ± 4.7
Day, Month 0; n=19, 20, 1526.3 ± 5.023.4 ± 5.422.0 ± 4.9
Morning, Month 3; n=19, 18, 1327.2 ± 5.123.8 ± 5.924.3 ± 3.5
Day, Month 3; n=19, 19, 1327.2 ± 4.724.4 ± 6.324.0 ± 3.9
Morning, Month 6; n=16, 19, 1128.3 ± 4.724.2 ± 5.324.4 ± 4.1
Day, Month 6; n=16, 19, 1128.2 ± 4.524.4 ± 5.325.3 ± 4.2
Morning, Month 9; n=16, 17, 927.2 ± 4.124.4 ± 5.425.0 ± 5.0
Day, Month 9; n=16, 17, 927.0 ± 4.525.6 ± 4.425.6 ± 4.7
Morning, Month 12; n=16, 16, 927.2 ± 5.425.5 ± 5.123.8 ± 5.4
Day, Month 12; n=16, 16, 926.3 ± 5.326.4 ± 4.924.7 ± 5.5
Morning, Month 18; n=15, 14, 1026.2 ± 4.124.9 ± 6.424.8 ± 6.1
Day, Month 18; n=15, 14, 1026.3 ± 3.725.9 ± 6.125.0 ± 7.0
Morning, Month 24; n=13, 13, 727.0 ± 5.224.8 ± 5.622.7 ± 5.1
Day, Month 24; n=13, 13, 726.7 ± 5.626.5 ± 5.123.8 ± 4.6
Morning, Month 30; n=9, 9, 527.4 ± 4.624.4 ± 6.125.1 ± 7.0
Day, Month 30; n=9, 9, 527.9 ± 4.225.1 ± 5.827.0 ± 5.3
Morning, Month 36; n=6, 11, 526.5 ± 5.323.1 ± 6.725.1 ± 6.8
Day, Month 36; n=5, 11, 525.2 ± 2.423.9 ± 6.326.3 ± 6.3
Morning, Endpoint; n=23, 20, 1625.1 ± 5.522.7 ± 6.322.8 ± 5.2
Day, Endpoint; 23, 20, 1625.1 ± 4.823.6 ± 6.223.0 ± 6.3
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 0.010
  • Duodopa Naïve · Wilcoxon tests · p = 0.073
SecondaryElectronic Diary: Morning and Day Scores (Tapping, Random Chase - Accuracy) From Baseline to Month 36

The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Tapping: Random chase speed' is defined as the number of correct taps of fields randomly selected by the computer per 20 seconds. 'Tapping random chase - accuracy' is the percentage of accurate random chase taps.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · percentage of accurate taps
Electronic Diary: Morning and Day Scores (Tapping, Random Chase - Accuracy) From Baseline to Month 36
percentage of accurate tapsDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Morning, Baseline (Month -3); n=20, 0, 092.0 ± 14.2NA ± NANA ± NA
Day, Baseline (Month -3); n=20, 0, 091.8 ± 7.8NA ± NANA ± NA
Morning, Month 0; n=19, 20, 1594.6 ± 4.590.0 ± 12.692.6 ± 6.3
Day, Month 0; n=19, 20, 1592.9 ± 6.891.3 ± 10.692.3 ± 7.0
Morning, Month 3; n=19, 18, 1390.5 ± 17.389.2 ± 11.689.1 ± 10.1
Day, Month 3; n=19, 19, 1392.5 ± 9.888.6 ± 13.689.8 ± 8.0
Morning, Month 6; n=16, 19, 1195.2 ± 4.489.0 ± 14.290.5 ± 7.7
Day, Month 6; n=16, 19, 1194.6 ± 3.588.7 ± 14.089.2 ± 11.6
Morning, Month 9; n=16, 17, 991.2 ± 8.190.8 ± 10.591.8 ± 6.3
Day, Month 9; n=16, 17, 992.4 ± 7.793.1 ± 7.292.5 ± 4.8
Morning, Month 12; n=16, 16, 992.2 ± 8.890.7 ± 11.490.6 ± 5.9
Day, Month 12; n=16, 16, 991.2 ± 7.692.5 ± 8.089.2 ± 7.9
Morning, Month 18; n=15, 14, 1090.2 ± 11.388.8 ± 14.686.8 ± 13.9
Day, Month 18; n=15, 14, 1091.6 ± 5.592.1 ± 9.285.4 ± 15.4
Morning, Month 24; n=13, 13, 791.7 ± 10.292.2 ± 9.689.0 ± 7.7
Day, Month 24; n=13, 13, 792.9 ± 6.793.4 ± 5.290.7 ± 6.3
Morning, Month 30; n=9, 9, 595.1 ± 3.385.9 ± 11.590.5 ± 9.1
Day, Month 30; n=9, 9, 593.6 ± 4.988.6 ± 8.691.2 ± 7.2
Morning, Month 36; n=6, 11, 583.5 ± 19.885.9 ± 14.889.7 ± 7.0
Day, Month 36; n=5, 11, 582.1 ± 16.988.4 ± 11.888.8 ± 7.5
Morning, Endpoint; n=23, 20, 1687.8 ± 18.783.8 ± 15.187.5 ± 8.1
Day, Endpoint; n=23, 20, 1687.3 ± 12.686.6 ± 14.386.7 ± 9.6
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 0.048
  • Duodopa Naïve · Wilcoxon tests · p = 0.030
SecondaryElectronic Diary: Morning and Day Scores (Drawing Impairment [Wavelet Method]) From Baseline to Month 36

The Electronic Diary consisted of 15 items addressing motor performance, complication of therapy, self-assessment, and various types of tapping. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Drawing impairment was assessed as a spiral score, where the participant is asked to draw a spiral. 1 is worst score, 10 is best.

Time frame:
Baseline (Month -3), Months 0, 3, 6, 9, 12, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
Electronic Diary: Morning and Day Scores (Drawing Impairment [Wavelet Method]) From Baseline to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Morning, Baseline (Month -3); n=20, 0, 04.0 ± 1.4NA ± NANA ± NA
Day, Baseline (Month -3); n=20, 0, 04.0 ± 1.2NA ± NANA ± NA
Morning, Month 0; n=19, 20, 154.1 ± 1.44.5 ± 1.65.0 ± 1.2
Day, Month 0; n=19, 20, 154.2 ± 1.34.3 ± 1.55.1 ± 1.2
Morning, Month 3; n=19, 18, 133.6 ± 1.24.3 ± 1.54.7 ± 1.5
Day, Month 3; n=19, 19, 133.8 ± 1.24.2 ± 1.44.8 ± 1.5
Morning, Month 6; n=16, 19, 113.8 ± 1.34.5 ± 1.74.5 ± 1.4
Day, Month 6; n=16, 19, 114.1 ± 1.04.6 ± 1.64.5 ± 1.7
Morning, Month 9; n=16, 17, 94.3 ± 1.24.1 ± 1.44.6 ± 1.5
Day, Month 9; n=16, 17, 94.3 ± 1.04.1 ± 1.24.5 ± 1.5
Morning, Month 12; n=16, 16, 94.1 ± 1.54.1 ± 1.25.0 ± 1.4
Day, Month 12; n=16, 16, 94.4 ± 1.24.1 ± 1.34.7 ± 1.4
Morning, Month 18; n=15, 14, 104.6 ± 1.34.4 ± 1.55.4 ± 1.8
Day, Month 18; n=15, 14, 104.6 ± 1.04.3 ± 1.54.9 ± 1.8
Morning, Month 24; n=13, 13, 74.3 ± 1.53.9 ± 1.35.2 ± 1.7
Day, Month 24; n=13, 13, 74.5 ± 1.43.9 ± 1.15.1 ± 1.7
Morning, Month 30; n=9, 9, 54.1 ± 1.44.4 ± 1.54.9 ± 1.5
Day, Month 30; n=9, 9, 54.5 ± 1.24.4 ± 1.44.8 ± 1.9
Morning, Month 36; n=6, 11, 54.4 ± 1.64.8 ± 1.85.3 ± 1.6
Day, Month 36; n=5, 11, 55.0 ± 0.94.6 ± 1.55.3 ± 1.3
Morning, Endpoint; n=23, 20, 164.5 ± 1.45.0 ± 1.85.3 ± 1.3
Day, Endpoint; n=23, 20, 164.8 ± 1.24.9 ± 1.75.3 ± 1.2
Statistical analysis
  • Duodopa Naïve · Wilcoxon tests · p = 0.208
  • Duodopa Naïve · Wilcoxon tests · p = 0.048
Other pre-specifiedUPDRS Total Score up to Month 36

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Part I score is the sum of answers to 'Mentation, Behavior and Mood' questions, with a score range from 0-16. Part II score is the sum of answers to 'Activities of Daily Living' questions, with a score range from 0-52. Part III score is the sum of answers to 'Motor Examination' questions, with a score range from 0-108. Total Score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale, with a score range from 0-176. Higher scores are associated with more disability.

Time frame:
Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
UPDRS Total Score up to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Month 0; n=27, 22, 1843.1 ± 16.746.2 ± 17.347.8 ± 16.4
Month 3; n=24, 22, 1842.4 ± 19.145.5 ± 18.246.8 ± 16.4
Month 6; n=25, 22, 1843.3 ± 21.443.5 ± 17.647.4 ± 13.2
Month 9; 5, 20, 1740.8 ± 22.445.1 ± 13.048.1 ± 17.8
Month 18; n=24, 20, 1745.2 ± 22.844.2 ± 16.148.5 ± 18.0
Month 24; n=23, 18, 1544.5 ± 25.340.2 ± 15.952.7 ± 15.5
Month 30; n=23, 17, 1347.1 ± 25.547.4 ± 19.050.2 ± 19.8
Month 36; n=21, 16, 1246.2 ± 27.847.1 ± 14.354.0 ± 25.3
Endpoint visit; n=27, 22, 1847.9 ± 25.850.8 ± 17.555.0 ± 23.0
Other pre-specifiedUPDRS Part I Score, up to Month 36

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Part I score is the sum of answers to 'Mentation, Behavior and Mood' questions, with a score range from 0-16. Higher scores are associated with more disability.

Time frame:
Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
UPDRS Part I Score, up to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Month 0; n=27, 22, 182.4 ± 1.82.0 ± 1.82.7 ± 1.8
Month 3; n=24, 22, 182.5 ± 1.72.0 ± 1.63.2 ± 2.3
Month 6; n=25, 22, 182.9 ± 1.92.3 ± 1.82.9 ± 2.1
Month 9; n=25, 20, 173.0 ± 1.92.9 ± 1.63.3 ± 2.3
Month 18; n=24, 20, 174.1 ± 3.02.7 ± 2.23.3 ± 2.6
Month 24; n=23, 18, 153.9 ± 2.83.0 ± 2.03.5 ± 2.1
Month 30; n=23, 17, 134.1 ± 3.23.5 ± 2.72.8 ± 2.0
Month 36; n=21, 16, 123.9 ± 3.13.9 ± 2.53.8 ± 3.3
Endpoint visit; n=27, 22, 183.9 ± 3.23.5 ± 2.64.0 ± 2.8
Other pre-specifiedUPDRS Part II Score, up to Month 36

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Part II score is the sum of answers to 'Activities of Daily Living' questions, with a score range from 0-52. Higher scores are associated with more disability.

Time frame:
Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
UPDRS Part II Score, up to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Month 0; n=27, 22, 1812.3 ± 5.113.7 ± 6.315.4 ± 5.9
Month 3; n=24, 22, 1812.0 ± 5.712.8 ± 7.115.0 ± 5.8
Month 6; n=25, 22, 1812.4 ± 6.713.4 ± 6.714.3 ± 4.4
Month 9; n=25, 20, 1711.8 ± 6.913.0 ± 5.514.4 ± 5.2
Month 18; n=24, 20, 1713.3 ± 7.212.9 ± 6.615.6 ± 5.8
Month 24; n=23, 18, 1512.9 ± 7.712.2 ± 6.217.2 ± 5.3
Month 30; n=23, 17, 1314.0 ± 8.514.6 ± 7.316.9 ± 6.3
Month 36; n=21, 16, 1213.9 ± 8.414.6 ± 5.416.8 ± 8.2
Endpoint visit; n=27, 22, 1814.6 ± 7.915.7 ± 6.417.3 ± 7.0
Other pre-specifiedUPDRS Part III Score, up to Month 36

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Parts I-III and Total Score, each question is measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Part III score is the sum of answers to 'Motor Examination' questions, with a score range from 0-108. Higher scores are associated with more disability.

Time frame:
Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
UPDRS Part III Score, up to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Month 0; n=27, 22, 1822.0 ± 9.723.4 ± 11.122.4 ± 9.8
Month 3; n=24, 22, 1821.6 ± 11.522.9 ± 11.321.9 ± 9.5
Month 6; n=25, 20, 1821.5 ± 14.122.8 ± 9.922.6 ± 8.6
Month 9; n=25, 20, 1719.9 ± 12.421.9 ± 8.122.9 ± 11.8
Month 18; n=24, 20, 1621.3 ± 12.621.7 ± 9.323.3 ± 11.1
Month 24; n=23, 18, 1521.4 ± 14.218.2 ± 9.825.4 ± 9.2
Month 30; n=23, 17, 1323.1 ± 15.622.6 ± 11.524.0 ± 12.1
Month 36; n=21, 16, 1222.0 ± 17.222.2 ± 7.928.0 ± 15.8
Endpoint visit; n=27, 22, 1723.1 ± 15.824.1 ± 9.828.6 ± 13.6
Other pre-specifiedUPDRS Part IV Score, up to Month 36

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. For Part IV, questions are measured on a 5-point scale of 0 (normal or no disease effect) to 4 (maximum negative effect) or 2-point scale (0 or 1). Part IV score is the sum of answers to 'Complications of Therapy' questions, with a score range from 0-23. Higher scores are associated with more disability.

Time frame:
Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
UPDRS Part IV Score, up to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Month 0; n=27, 22, 186.5 ± 2.77.1 ± 3.47.2 ± 3.0
Month 3; n=24, 22, 186.3 ± 2.97.8 ± 3.16.7 ± 3.4
Month 6; n=25, 22, 186.5 ± 2.77.1 ± 2.87.7 ± 3.2
Month 9; n=25, 20, 176.1 ± 3.37.3 ± 3.37.5 ± 4.2
Month 18; n=24, 20, 176.5 ± 3.37.0 ± 3.27.6 ± 2.8
Month 24; n=23, 18, 156.3 ± 4.36.8 ± 3.66.6 ± 2.5
Month 30; n=22, 17, 136.2 ± 3.76.6 ± 3.36.5 ± 2.8
Month 36; n=21, 16, 126.4 ± 3.06.4 ± 2.45.5 ± 1.8
Endpoint visit; n=26, 22, 186.5 ± 3.07.5 ± 3.06.7 ± 2.7
Other pre-specifiedEQ-5D Descriptive Systems Summary Index Score, up to Month 36

The EQ-5D is a participant-answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 to 1.00 with positive change indicating improvement.

Time frame:
Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
EQ-5D Descriptive Systems Summary Index Score, up to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Month 0; n=27, 22, 180.67 ± 0.270.68 ± 0.270.62 ± 0.24
Month 3; n=24, 22, 180.61 ± 0.300.70 ± 0.290.57 ± 0.32
Month 6; n=25, 21, 180.64 ± 0.260.71 ± 0.220.57 ± 0.32
Month 9; n=25, 20, 170.61 ± 0.330.66 ± 0.230.59 ± 0.30
Month 18; n=24, 20, 160.64 ± 0.230.66 ± 0.340.53 ± 0.35
Month 24; n=21, 18, 150.58 ± 0.330.67 ± 0.260.47 ± 0.32
Month 30; n=22, 17, 120.55 ± 0.280.69 ± 0.190.52 ± 0.28
Month 36; n=21, 15, 110.52 ± 0.310.57 ± 0.280.51 ± 0.25
Endpoint visit; n=26, 22, 170.54 ± 0.310.60 ± 0.250.46 ± 0.33
Other pre-specifiedEQ-5D Visual Analog Scale (VAS) Score, up to Month 36

The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.'

Time frame:
Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing value assigned to treatment for the participant)
Reported as:
Mean · units on a scale
EQ-5D Visual Analog Scale (VAS) Score, up to Month 36
units on a scaleDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Month 0; n=27, 22, 180.68 ± 0.180.65 ± 0.180.58 ± 0.23
Month 3; n=24, 22, 180.65 ± 0.190.63 ± 0.180.58 ± 0.20
Month 6; n=25, 21, 180.60 ± 0.220.65 ± 0.160.59 ± 0.18
Month 9; n=25, 20, 170.68 ± 0.140.69 ± 0.150.58 ± 0.19
Month 18; n=24, 20, 160.62 ± 0.200.60 ± 0.200.55 ± 0.27
Month 24; n=21, 17, 150.64 ± 0.180.60 ± 0.200.63 ± 0.12
Month 30; n=22, 17, 120.56 ± 0.200.67 ± 0.140.65 ± 0.17
Month 36; n=21, 15, 110.56 ± 0.170.61 ± 0.180.62 ± 0.19
Endpoint visit; n=26, 22, 170.57 ± 0.160.61 ± 0.170.57 ± 0.21

Adverse events

Collected over Events presented are treatment-emergent (those with a start date beyond or equal to first day of study treatment but within 7 days [for adverse events] or 30 days [for serious adverse events] after last study drug intake). Treatment period was 36 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Duodopa Naïve—24/36 (66.7%)29/36 (80.6%)
Duodopa Non-naïve < 2 Years—17/22 (77.3%)22/22 (100%)
Duodopa Non-naïve ≥ 2 Years—14/18 (77.8%)17/18 (94.4%)
Most frequent serious events
Showing 10 of 106
Most frequent serious events
EventDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Medical device changeSurgical and medical procedures9/369/223/18
PneumoniaInfections and infestations4/363/221/18
FallInjury, poisoning and procedural complications1/363/222/18
Medical device removalSurgical and medical procedures0/363/220/18
Medical device complicationInjury, poisoning and procedural complications1/360/222/18
DehydrationMetabolism and nutrition disorders1/360/222/18
DyskinesiaNervous system disorders2/361/222/18
HallucinationPsychiatric disorders4/361/221/18
AnaemiaBlood and lymphatic system disorders1/362/221/18
Femur fractureInjury, poisoning and procedural complications0/362/220/18
Most frequent other events
Showing 10 of 140
Most frequent other events
EventDuodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 Years
Device dislocationInjury, poisoning and procedural complications7/368/225/18
Blood homocysteine increasedInvestigations2/364/226/18
Excessive granulation tissueSkin and subcutaneous tissue disorders6/367/222/18
Device related infectionInfections and infestations4/366/224/18
Micturition urgencyRenal and urinary disorders0/366/222/18
Medical device changeSurgical and medical procedures6/365/221/18
ConstipationGastrointestinal disorders8/363/224/18
Urinary tract infectionInfections and infestations2/364/224/18
DepressionPsychiatric disorders7/364/222/18
HallucinationPsychiatric disorders7/362/222/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)Duodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 YearsTotal
Mean64.6 ± 6.465.4 ± 5.266.6 ± 8.765.4 ± 6.8
Sex: Female, Male
Sex: Female, Male(Participants)Duodopa NaïveDuodopa Non-naïve < 2 YearsDuodopa Non-naïve ≥ 2 YearsTotal
Female117624
Male16151243
08

Study locations

No study locations are listed for this record.

09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Mar 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 5 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2005
First posted
Sep 1, 2005
Start
Mar 2006
Primary completionActual
Mar 2011
CompletionActual
Apr 2011
Results first posted
Jul 18, 2016
Last update
Jul 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00141518
Responsible party
Sponsor
First posted
Sep 1, 2005
Start date
Mar 2006
Primary completion
Mar 2011
Completion
Apr 2011
Results posted
Jul 18, 2016
Last update
Jul 18, 2016

Study contacts

Lars Bergmann, MD
study director · AbbVie
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion